

**WORLD  
ANTI-DOPING  
AGENCY**  
play true

ISTI, ISL

# ***Athlete Biological Passport Operating Guidelines***

**Version 7.1**

June 2019

## Table of Contents

Content.....	3
<b>Part One: Introduction and Objectives.....</b>	<b>4</b>
1.1 Introduction to the <i>Athlete Biological Passport</i> .....	4
1.2 Objectives.....	4
<b>Part Two: Modules, Management and Administration .....</b>	<b>5</b>
<b>2.1 Modules .....</b>	<b>5</b>
2.1.1 Haematological Module .....	5
2.1.2 Steroidal Module .....	6
<b>2.2 Resources, Partner Roles and Responsibilities .....</b>	<b>7</b>
2.2.1 Resources.....	7
2.2.2 Specific Partner Responsibilities .....	7
2.2.2.1 <i>Anti-Doping Organization (ADO)</i> .....	7
2.2.2.2 <u>Athlete Passport Management Unit (APMU)</u> .....	8
2.2.2.3 Laboratory.....	8
2.2.2.4 <u>Experts</u> .....	9
<b>2.3 ABP Management and Administration .....</b>	<b>10</b>
2.3.1 <i>Testing</i> and Defining the Target <i>Athletes</i> .....	10
2.3.2 <i>Athlete</i> Information.....	10
2.3.3 Standardization through <i>ADAMS</i> .....	11
2.3.4 <u>APMU Report</u> .....	11
2.3.5 Recommended Administrative Sequence.....	12
2.3.6 <i>ABP</i> Administrative Sequence Graphic .....	13
<b>2.4 <u>Passport Custody and Passport Sharing</u> .....</b>	<b>15</b>
2.4.1 Role of the <u>Passport Custodian</u> .....	15
2.4.2 Attribution and Transfer of <u>Passport Custody</u> .....	16
<b>2.5 Definitions.....</b>	<b>16</b>
2.5.1 2015 <i>Code</i> Defined Terms .....	16
2.5.2 <i>ISTI</i> Defined Terms .....	21
2.5.3 <i>ISL</i> Defined Terms.....	22
2.5.4 <i>ISPPPI</i> Defined Terms .....	24
2.5.5 <i>ABP</i> Operating Guidelines and Related TDs Defined Terms .....	24
<b>Part Three: Mandatory Protocols.....</b>	<b>26</b>
<b>3.0 Scope .....</b>	<b>26</b>
<b>3.1 Collection, Storage and Transport of <i>ABP</i> Blood Samples (<i>ISTI Annex K</i>) .....</b>	<b>27</b>
<b>3.2 Blood Analytical Requirements for the Athlete Biological Passport .....</b>	<b>32</b>
<b>3.3 Endogenous Anabolic Androgenic Steroids Measurement and Reporting.....</b>	<b>37</b>
<b>3.4 Results Management Requirements and Procedures for the Athlete Biological Passport (<i>ISTI Annex L</i>).....</b>	<b>54</b>
<b>3.5 Athlete Passport Management Unit Requirements and Procedures .....</b>	<b>63</b>
<b>Part Four: Collaboration Agreement Template .....</b>	<b>85</b>

## Content

This document is divided into four parts.

**Part One** provides background and context for the creation of the *ABP*, introduces the Haematological and Steroidal Modules of the Passport and explains the role of the *ABP* Operating Guidelines in supporting *ADOs*.

**Part Two** describes the Modules and explains the principles for the implementation of the *ABP* by an *ADO*.

**Part Three** contains Annexes of the *International Standard* for Testing and Investigation (*ISTI*) in connection with Technical Documents that specify mandatory protocols to be followed by *ADOs*, *Laboratories*, and APMUs in order to run an *ABP* program.

**Part Four** includes a template agreement developed by *WADA* for the sharing of Passport information between multiple *ADOs* (supported by *ADAMS*).

---

## Part One: Introduction and Objectives

### 1.1 Introduction to the *Athlete Biological Passport*

The term “athlete biological passport” was first proposed in the early 2000s by the scientific community when monitoring of select haematological variables (*Markers* of blood doping) was identified as a means to define an individual’s haematological profile. In conjunction with several stakeholders and medical experts, the World Anti-Doping Agency (*WADA*) began to further develop, harmonize and validate this concept. The result was a formal operating guideline and mandatory standards known as the *Athlete Biological Passport (ABP)*, first published in 2009, which concerned exclusively the Haematological Module.

In 2014, the initial system was complemented with the Steroidal Module, which was launched in order to establish longitudinal profiles of an *Athlete’s* steroid variables.

The framework proposed in these Guidelines builds on existing anti-doping infrastructure to promote harmonization in *ABP* Programs, facilitate exchange of information and mutual recognition of data and, consequently, to enhance efficiencies in the operation of Anti-Doping Activities.

These Guidelines provide a harmonized process for both the Haematological Module and the Steroidal Module of the *ABP*, following nearly identical administrative procedures in *ADAMS*.

As with all Guidelines, this document is subject to ongoing review and assessment to ensure it continues to reflect best practice moving forward. *WADA* encourages feedback on this document and recommends stakeholders to consult *WADA’s* Web site, <http://www.wada-ama.org> for the latest version.

### 1.2 Objectives

The principal objectives of integrating the *ABP* into the larger framework of a robust anti-doping program are the following:

1. The *ABP* can be used to identify *Athletes* requiring further attention through intelligent, timely interpretation of Passport data. The *ABP* provides valuable information that can be used to direct *Target Testing* or investigations more effectively. The *ABP* can notably be used as a complement to analytical methods to further refine and strengthen overall anti-doping strategies:
  - i) For the Haematological Module, this could be, for example, *Testing* for Erythropoiesis-Stimulating Agents<sup>1</sup> (ESAs) or homologous blood

---

<sup>1</sup>Described in Section S2.1 of the *Prohibited List* as erythropoietins and agents affecting erythropoiesis.

transfusion (HBT).

- ii) For the Steroidal Module, this could be, for example, the use of Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS) to detect endogenous steroids administered exogenously.
2. A Passport may be used to pursue an Anti-Doping Rule Violation (ADRV) in accordance with World Anti-Doping Code (*Code*) Article 2.2. Through changes in biological *Markers* of doping collated over an *Athlete's* career, the *ABP* can be used to establish 'Use' per *Code* Article 2.2 without necessarily relying on the detection of a particular *Prohibited Substance* or *Prohibited Method*. This approach has proven effective in establishing ADRVs without having to rely on traditional analytical approaches.

## Part Two: Modules, Management and Administration

### 2.1 Modules

#### 2.1.1 Haematological Module

The Haematological Module collects information on *Markers* of blood doping. This Module aims to identify the *Use of Prohibited Substances* and/or *Prohibited Methods* for the enhancement of oxygen transport or delivery, including the *Use* of ESAs and any form of blood transfusion or manipulation.

In addition to identifying the use of ESAs included under section S2 of the *Prohibited List* (Peptide Hormones, Growth Factors, Related Substances and Mimetics), the Haematological Module also seeks to identify the *Use of Prohibited Methods* categorized under section M1 of the *Prohibited List* (Manipulation of Blood and Blood Components).

The following blood variables are considered within the *ABP* Haematological Module:

ABPS:	Abnormal Blood Profile Score
HCT:	Haematocrit
HGB:	Haemoglobin
IRF:	Immature reticulocyte fraction
MCH:	Mean corpuscular haemoglobin
MCHC:	Mean corpuscular haemoglobin concentration
MCV:	Mean corpuscular volume
OFFS:	OFF-hr Score

---

PLT:	Platelets
RBC:	Red blood cell (erythrocyte) count
RDW-SD:	Red cell distribution width (standard deviation)
RET#:	Reticulocyte count
RET%:	Reticulocytes percentage
WBC:	White Blood Cells

### 2.1.2 Steroidal Module

The Steroidal Module collects information on *Markers* of steroid doping. The Module aims to identify endogenous anabolic androgenic steroids (EAAS) when administered exogenously and other anabolic agents, such as selective androgen receptor modulators (SARMS) categorized under Section S1.2 of the *Prohibited List*. The Steroidal Module is also an effective means to identify *Samples* which may have been tampered with or exchanged with the urine of another individual (*Code Article 2.5*).

The following *Markers* are considered within the *ABP Steroidal Module*, as detailed in the Technical Document on Endogenous Anabolic Androgenic Steroids Measurement and Reporting (TDEAAS, see Section 3.3 below):

- testosterone (T);
- epitestosterone (E);
- androsterone (A);
- etiocholanolone (Etio);
- 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol (5 $\alpha$ Adiol);
- 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol (5 $\beta$ Adiol);

and the following ratios:

- testosterone to epitestosterone (T/E);
- androsterone to testosterone (A/T);
- androsterone to etiocholanolone (A/Etio);
- 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol to 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol (5 $\alpha$ Adiol/5 $\beta$ Adiol);  
and
- 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol to epitestosterone (5 $\alpha$ Adiol/E).

## 2.2 Resources, Partner Roles and Responsibilities

The roles and responsibilities of the various partners implementing the *ABP* include test planning, conducting the *Sample* collection, profile interpretation and results management.

### 2.2.1 Resources

The following resources are required to adopt and implement the *ABP*:

- Access to a network of Doping Control Officers (DCOs) and Blood Collection Officers (BCOs) where necessary, operating in locations where target *Athletes* will be present.
- An effective whereabouts management system to facilitate *Athlete* location (i.e. *ADAMS*).
- Access to *ADAMS*, to administer the *ABP* Program.
- An APMU associated with a *Laboratory* for the management of *ABP* processes.
- An Expert panel chosen by the *ADO* and/or APMU qualified for the review of Passports.

[Comment to 2.2.1: Access to the *ADAMS Biological Passport Guide* is available at the following link:

<http://adams-docs.wada-ama.org/display/EN/ADAMS+Biological+Passport+guide>]

### 2.2.2 Specific Partner Responsibilities

#### 2.2.2.1 Anti-Doping Organization (ADO)

The *ADO* is responsible for:

- Adopting, implementing and administrating an *ABP* program in accordance with these Guidelines, including compliance with the *ISTI*.
- Contracting an APMU to manage the *ABP* program.
- Ensuring that recommendations received from the APMU are followed by effective, targeted, timely and appropriate *Testing*.
- Establishing, and implementing a test distribution plan, in consultation with the APMU.
- Sharing of relevant information with internal investigations personnel and other *ADOs* (when appropriate).
- When the *ADO* is the Passport Custodian, following up on *Adverse Passport Findings (APFs)* in accordance with *Code* and *ISTI* requirements.

- Informing the *Athlete* in case the Passport indicates a likely pathology as determined by the Experts.

### **2.2.2.2 Athlete Passport Management Unit (APMU)**

The APMU is responsible for:

- Timely management of the Passports in *ADAMS* on behalf of the Passport Custodian.
- Performing Passport assessments to make timely *Target Testing* recommendations to the *Anti-Doping Organization (ADO)* via the APMU Report in *ADAMS* when appropriate.
- Managing the review of atypical Passports according to Annex L of the International Standard for Testing and Investigations (ISTI), including, but not limited to, the following:
  - Issuing and updating APMU Reports in *ADAMS*,
  - In case of an *Atypical Passport Finding (ATPF)*, or when a review is otherwise justified, assigning and liaising with the Expert panel as required,
  - Compiling all necessary information to establish an Athlete Biological Passport (ABP) Documentation Package, and
  - Declaring *Adverse Passport Findings (APFs)* to the Passport Custodian and *WADA*.
- Assessing and managing Passport Sample validity in *ADAMS*, in consultation with the Experts or Laboratories when necessary.
- Providing support to the Passport Custodian in defining priorities in order to optimize the efficiency of their *ABP* program. These priorities may include, but are not limited to, cost efficiency, special analyses, Test Distribution Plans, and *Target Testing*.

### **2.2.2.3 Laboratory**

The *Laboratory* or WADA-Approved Laboratory for the ABP is responsible for:

- Blood analysis: perform blood analysis in compliance with the Technical Document on Blood Analytical Requirements for the Athlete Biological Passport (Section 3.2 below).
- Urine analysis: perform urine analysis in compliance with the Technical Document on Endogenous Anabolic Androgenic Steroids Measurement and Reporting (Section 3.3 below) for the measurement and reporting of urinary steroid profiles.

- Issuing a Certificate of Analysis or Laboratory Documentation Package as applicable.
- Providing additional information for interpretation of results and for complementary analysis.


#### **2.2.2.4 Experts**

The Experts are responsible for:

- Reviewing Passport data and results from the Adaptive Model in *ADAMS* provided by the APMU. The review shall identify any possible pathological or confounding conditions that may have impacted an *Athlete's* analytical results.
- Recommending follow-up *Testing* and/or suggesting possible clinical testing that may be required to a) confirm the assessment or b) collect further evidence to support or confirm possible pathologies.
- Reviewing any explanations given by the *Athlete* and providing an opinion on whether the Passport was likely the result of the Use of a Prohibited Substance or Prohibited Method.
- Working with the relevant APMU as required, and providing support as necessary throughout the results management and hearing process.

## 2.3 ABP Management and Administration

An *ABP* program is administered and managed by an APMU on behalf of the *ADO*. The APMU is the link between the Passport Custodian, the Laboratories, and the Expert panel. Within each Passport in *ADAMS*, the APMU Report provides a record of these various interactions for efficient follow-up by the Passport Custodian, *WADA* and other *ADOs* with whom the Passport is shared through *ADAMS*.



### 2.3.1 Testing and Defining the Target Athletes

An *ABP Testing* Program must follow the *ISTI*, the Technical Document for Sport Specific Analysis (TDSAA) and applicable Technical Documents specific to the *ABP* (Part Three below).

Targeted tests that follow the recommendations of the APMU should be privileged over Random Selection Testing to improve the effectiveness of the *ABP*. In general, the effectiveness of the *ABP* to detect doping is improved where both *In-* and *Out-of-Competition Testing* and No Advance Notice Testing are distributed strategically throughout the year.

*[Comment to 2.3.1: For the Haematological Module, it is recommended to use data from samples collected 5 days apart or more to optimize the statistical significance of the data. This does not preclude Testing an Athlete less than five (5) days apart, notably and without limitation, when a potential risk of doping practices has been identified. The validity of the Samples and their inclusion in the Expert review is in any event not put in question by the collection frequency.]*

Without limitation, the criteria listed in *ISTI* Article 4.2 are the factors that may be considered in determining the target population for the *ABP* in the context of an *ADO's* overall Test Distribution Plan (TDP).

### 2.3.2 Athlete Information

Given that additional information is required from *Athletes* beyond what is collected in traditional *Doping Control* documentation pursuant to the *ISTI*, supplemental or revised documentation may be required. Such documentation may be collected as

appropriate, both prior to and after *Testing*, for APMU assessment and Experts' review as required.

For *ABP* blood *Samples*, in addition to the mandatory information set out in *ISTI* Article 7.4.5, which must be recorded as a part of all Sample Collection Sessions, the information listed in *ISTI* K.2.6 (Section 3.1 below) shall be recorded in a specific *ABP* Supplementary Form or a related form to be signed by the *Athlete*.

See the available *ABP* Supplementary Form template:

<https://www.wada-ama.org/en/resources/world-anti-doping-program/athlete-biological-passport-supplementary-report-form>

### 2.3.3 Standardization through *ADAMS*

The *ABP* Program is administered through *WADA's Anti-Doping Administration and Management System (ADAMS)*, a secure online database management tool for data entry, storage, sharing, and reporting, designed to assist stakeholders and *WADA* in their anti-doping operations. An essential element of the *ABP*, the Adaptive Model, is fully integrated into *ADAMS*. Only programs that fully utilize *ADAMS* can be considered *ABP* Programs.

Standardization and harmonization of *ABP* programs is achieved through the use of *ADAMS*. This ensures that all mandatory requirements are met and that the *Athlete Passports* are shared and stored securely, all in accordance with the *International Standard for the Protection of Privacy and Personal Information (ISPPPI)*. Furthermore, *ADAMS* facilitates prompt exchange of information between *ADOs*, *APMUs*, Laboratories and/or WADA-Approved Laboratories for the ABP, Sample Collection Personnel, and *WADA*.

### 2.3.4 APMU Report

The APMU Report is a central element in the administrative sequence of the *ABP* that shall be entered and maintained by the APMU in *ADAMS*. The APMU Report provides an up-to-date overview of the current status of an *Athlete's Passport* together with recommendations, as appropriate, for efficient follow-up by the Passport Custodian. The APMU Report serves to update the Passport Custodian, *WADA* and other *ADOs* with whom the Passport is shared. In addition, it provides a record of events associated with a Passport in *ADAMS*.

The APMU Report may include, without limitations:

- Assessments of *Sample* validity by the APMU and/or Experts;
- Recommendations for complementary Analytical Testing (*e.g.*, ESAs, HIF stabilizers, confirmation of steroid profile, GC/C/IRMS, long-term steroid *Metabolites*, IGF-I, etc.) on *Samples* collected;


- Recommendations for further Analytical Testing on *Samples* collected previously;
- Recommendations for storing of *Samples* for extended periods of time for Further Analysis;
- *Target Testing* recommendations based on available data and Experts' recommendations; and a summary of any recent Expert reviews.

### **2.3.5 Recommended Administrative Sequence**


The following outlines the suggested sequence of interactions between the *Athlete*, Sample Collection Personnel, *ADOs*, Laboratory(ies), *ADAMS*, *APMUs*, and Expert panels to establish, follow up and review an individual *Athlete's* Passport in an effective and efficient manner.

The recommended administrative sequence outlined below may be modified or adapted to merge with existing anti-doping infrastructure, procedures and mechanisms as required. However these Guidelines aim to ensure that *ADOs* establish a process that demonstrates transparency in the planning, interpretation and results management aspects of an *ABP*.

## 2.3.6 ABP Administrative Sequence Graphic



## ABP Administrative Sequence Graphic, cont.



<sup>2</sup> When an ABP blood Sample is collected, the ADO must consider whether the collection of concomitant urine or blood Samples is warranted, under the circumstances, to perform traditional analysis. For Out-of-Competition Testing, it is recommended to collect urine Samples together with the blood Sample(s) in order to permit Analytical Testing for ESAs when required.

<sup>3</sup> For the Steroidal Module, where the Adaptive Model identifies an ATPF for elevated T/E, the Laboratory shall proceed with a Confirmation Procedure including GC-C-IRMS analysis. If the Laboratory receives a "Suspicious Steroid Profile Confirmation Procedure Request," the Laboratory shall proceed with the Confirmation Procedure(s), including the GC-C-IRMS analysis, unless, after contacting the Testing Authority, the Testing Authority can justify within 7 calendar days that the Confirmation Procedure(s) is/are not necessary (see TDEAAS, Section 3.3 below, and Annex L – ISTI, Section 3.4 below).

## 2.4 Passport Custody and Passport Sharing

For any individual *Athlete*, only one Passport should be established. Using *ADAMS* for the management of Passport information, *ADOs* enhance efficiency and program effectiveness through exchange of information and mutual recognition of program outcomes. Such coordination and reciprocal agreement reduce unnecessary duplication in resource expenditure and foster enhanced confidence among *ADOs* and *Athletes* alike.

All *Doping Control* biological results obtained for an *Athlete* are collated in his Passport regardless of the Testing Authority. Only a complete *Athlete's Passport* allows the correct determination of *Atypical Passport Findings* in *ADAMS*. Passport administration and possible results management can then follow in compliance with the *Code* with the assurance that the Passports are complete. *ADOs* that fail to share Passport data via *ADAMS* do not operate an *ABP* program.

Within the framework provided by the *ISPPPI*, *ADOs* are encouraged to coordinate their activities where multiple *ADOs* have *Testing* jurisdiction over a single *Athlete* and multiple *ADOs* may wish to perform Passport Testing. In the interests of a "one *Athlete* – one Passport" principle, *ADOs* should work cooperatively to see that *Testing* is coordinated appropriately with all results collated in the *Athlete's Passport* in *ADAMS*.

### 2.4.1 Role of the Passport Custodian

Any individual *Athlete* has a Passport Custodian that ensures that all *ADOs* that have *Testing* jurisdiction over the *Athlete* do not work in isolation. The Passport Custodian is responsible for sharing Passport information with other *ADOs* to ensure proper coordination and best use of resource expenditure. *WADA* has developed a template agreement for the sharing of Passport information between multiple *ADOs* (supported by *ADAMS*), which is included herein in Part Four.

In the case of an *ATPF*, or when a review is otherwise justified, the Passport Custodian is responsible for initiating the Passport review process via its APMU and, if an *APF* is declared, for results management of the Passport in compliance with Annex L of the *ISTI* (Section 3.4 below), regardless of whether another *ADO* was the Testing Authority of the test that triggered the *ATPF*.

Where the Testing Authority is not the Passport Custodian, the Testing Authority that initiated and directed the *Sample* collection maintains the responsibility for additional Analytical Testing of the *Sample*, including the performance of further Confirmation Procedure(s) upon requests generated automatically by the Adaptive Model of the *ABP* in *ADAMS* (e.g. *GC/C/IRMS* triggered by elevated *T/E*) or as requested by the APMU (e.g. *GC/C/IRMS* requested due to abnormal secondary *Markers* of the urinary

“longitudinal steroid profile”; ESA tests due to suspicious haematological *Marker* values).

## 2.4.2 Attribution and Transfer of Passport Custody

In *ADAMS*, Passport custody is attributed to the Testing Authority that first tests the *Athlete*, independently of whether it is an *ABP* haematological or steroid test or both. This process ensures that the custody will most likely automatically be assigned to the organization that has a real interest in the *Athlete*.<sup>4</sup>

Passport custody can be transferred in *ADAMS* to another *ADO* with *Testing* jurisdiction over the *Athlete*.<sup>5</sup>

## 2.5 Definitions

This document includes defined terms from the *Code*, and these *International Standards (IS)*: *ISTI*, *ISL* and *ISPPPI*. *Code* terms are written in italics. *IS* terms are underlined.

### 2.5.1 2015 *Code* Defined Terms

***ADAMS***: The Anti-Doping Administration and Management System is a Web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and *WADA* in their anti-Doping operations in conjunction with data protection legislation.

***Administration***: Providing, supplying, supervising, facilitating, or otherwise participating in the *Use* or *Attempted Use* by another *Person* of a *Prohibited Substance* or *Prohibited Method*. However, this definition shall not include the actions of bona fide medical personnel involving a *Prohibited Substance* or *Prohibited Method* used for genuine and legal therapeutic purposes or other acceptable justification and shall not include actions involving *Prohibited Substances* which are not prohibited in *Out-of-Competition Testing* unless the circumstances as a whole demonstrate that such *Prohibited Substances* are not intended for genuine and legal therapeutic purposes or are intended to enhance sport performance.

---

<sup>4</sup> When the *Athlete* is first tested by a *Major Event Organizer (MEO)*, Passport custody is attributed to the *IF*. When a *NADO* first tests an *Athlete* with a different sport nationality, Passport custody is attributed to the *IF*. This can later be reassigned to another *NADO* if appropriate.

<sup>5</sup> If no agreement can be found on the Passport custody, *WADA* shall determine which *ADO* is the *Athlete's Passport Custodian*. *WADA* shall not rule on this without consulting the *ADOs* involved.

**Adverse Analytical Finding (AAF):** A report from a WADA-accredited laboratory or other WADA-approved laboratory that, consistent with the International Standard for Laboratories and related Technical Documents, identifies in a *Sample* the presence of a *Prohibited Substance* or its *Metabolites* or *Markers* (including elevated quantities of endogenous substances) or evidence of the *Use of a Prohibited Method*.

**Adverse Passport Finding (APF):** A report identified as an *Adverse Passport Finding* as described in the applicable *International Standards*

**Anti-Doping Organization (ADO):** A *Signatory* that is responsible for adopting rules for initiating, implementing or enforcing any part of the *Doping Control* process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other *Major Event Organizations* that conduct *Testing* at their *Events*, WADA, International Federations, and *National Anti-Doping Organizations*.

**Athlete:** Any *Person* who competes in sport at the international level (as defined by each International Federation) or the national level (as defined by each *National Anti-Doping Organization*). An *Anti-Doping Organization* has discretion to apply anti-doping rules to an *Athlete* who is neither an *International-Level Athlete* nor a *National-Level Athlete*, and thus to bring them within the definition of "Athlete." In relation to *Athletes* who are neither *International-Level* nor *National-Level Athletes*, an *Anti-Doping Organization* may elect to: conduct limited *Testing* or no *Testing* at all; analyze *Samples* for less than the full menu of *Prohibited Substances*; require limited or no whereabouts information; or not require advance *TUEs*. However, if an Article 2.1, 2.3 or 2.5 anti-doping rule violation is committed by any *Athlete* over whom an *Anti-Doping Organization* has authority who competes below the international or national level, then the *Consequences* set forth in the *Code* (except Article 14.3.2) must be applied. For purposes of Article 2.8 and Article 2.9 and for purposes of anti-doping information and education, any *Person* who participates in sport under the authority of any *Signatory*, government, or other sports organization accepting the *Code* is an *Athlete*.

*[Comment to Athlete: This definition makes it clear that all International- and National-Level Athletes are subject to the anti-doping rules of the Code, with the precise definitions of international- and national-level sport to be set forth in the anti-doping rules of the International Federations and National Anti-Doping Organizations, respectively. The definition also allows each National Anti-Doping Organization, if it chooses to do so, to expand its anti-doping program beyond International- or National-Level Athletes to competitors at lower levels of Competition or to individuals who engage in fitness activities but do not compete at all. Thus, a National Anti-Doping Organization could, for example, elect to test recreational-level competitors but not require advance TUEs. But an anti-doping rule violation involving an Adverse Analytical Finding or Tampering results in all of the Consequences provided for in the Code (with the exception of Article 14.3.2). The decision on whether Consequences apply to recreational-level*

*Athletes who engage in fitness activities but never compete is left to the National Anti-Doping Organization. In the same manner, a Major Event Organization holding an Event only for masters-level competitors could elect to test the competitors but not analyze Samples for the full menu of Prohibited Substances. Competitors at all levels of Competition should receive the benefit of anti-doping information and education.]*

**Athlete Biological Passport (ABP):** The program and methods of gathering and collating data as described in the International Standard for Testing and Investigations and International Standard for Laboratories.

**Atypical Finding (ATF):** A report from a WADA-accredited laboratory or other WADA-approved laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an *Adverse Analytical Finding*.

**Atypical Passport Finding (ATPF):** A report described as an *Atypical Passport Finding* as described in the applicable *International Standards*.

**CAS:** The Court of Arbitration for Sport.

**Code:** The World Anti-Doping Code.

**Competition:** A single race, match, game or singular sport contest. For example, a basketball game or the finals of the Olympic 100-meter race in athletics. For stage races and other sport contests where prizes are awarded on a daily or other interim basis the distinction between a *Competition* and an *Event* will be as provided in the rules of the applicable International Federation.

**Consequences of Anti-Doping Rule Violations (Consequences):** An *Athlete's* or other *Person's* violation of an anti-doping rule may result in one or more of the following: (a) *Disqualification* means the *Athlete's* results in a particular *Competition* or *Event* are invalidated, with all resulting *Consequences* including forfeiture of any medals, points and prizes; (b) *Ineligibility* means the *Athlete* or other *Person* is barred on account of an anti-doping rule violation for a specified period of time from participating in any *Competition* or other activity or funding as provided in Article 10.12.1; (c) *Provisional Suspension* means the *Athlete* or other *Person* is barred temporarily from participating in any *Competition* or activity prior to the final decision at a hearing conducted under Article 8; (d) *Financial Consequences* means a financial sanction imposed for an anti-doping rule violation or to recover costs associated with an anti-doping rule violation; and (e) *Public Disclosure* or *Public Reporting* means the dissemination or distribution of information to the general public or *Persons* beyond those *Persons* entitled to earlier notification in accordance with Article 14. Teams in *Team Sports* may also be subject to *Consequences* as provided in Article 11.

**Doping Control:** All steps and processes from test distribution planning through to ultimate disposition of any appeal including all steps and processes in between such

as provision of whereabouts information, *Sample* collection and handling, laboratory analysis, *TUEs*, results management and hearings.

**Event:** A series of individual *Competitions* conducted together under one ruling body (e.g., the Olympic Games, FINA World Championships, or Pan American Games).

**In-Competition:** Unless provided otherwise in the rules of an International Federation or the ruling body of the *Event* in question, "*In-Competition*" means the period commencing twelve hours before a *Competition* in which the *Athlete* is scheduled to participate through the end of such *Competition* and the *Sample* collection process related to such *Competition*.

*[Comment to In-Competition: An International Federation or ruling body for an Event may establish an "In-Competition" period that is different than the Event Period.]*

**International Event:** An *Event* or *Competition* where the International Olympic Committee, the International Paralympic Committee, an International Federation, a *Major Event Organization*, or another international sport organization is the ruling body for the *Event* or appoints the technical officials for the *Event*.

**International-Level Athlete:** *Athletes* who compete in sport at the international level, as defined by each International Federation, consistent with the International Standard for Testing and Investigations.

*[Comment to International-Level Athlete: Consistent with the International Standard for Testing and Investigations, the International Federation is free to determine the criteria it will use to classify Athletes as International-Level Athletes, e.g., by ranking, by participation in particular International Events, by type of license, etc. However, it must publish those criteria in clear and concise form, so that Athletes are able to ascertain quickly and easily when they will become classified as International-Level Athletes. For example, if the criteria include participation in certain International Events, then the International Federation must publish a list of those International Events.]*

**International Standard:** A standard adopted by WADA in support of the *Code*. Compliance with an *International Standard* (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the *International Standard* were performed properly. *International Standards* shall include any Technical Documents issued pursuant to the *International Standard*.

**Major Event Organizations (MEOs):** The continental associations of *National Olympic Committees* and other international multi-sport organizations that function as the ruling body for any continental, regional or other *International Event*.

**Marker:** A compound, group of compounds or biological variable(s) that indicates the *Use of a Prohibited Substance* or *Prohibited Method*.

**Metabolite:** Any substance produced by a biotransformation process.

**National Anti-Doping Organization (NADO):** The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of *Samples*, the management of test results, and the conduct of hearings at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country's *National Olympic Committee* or its designee.

**National Event:** A sport *Event* or *Competition* involving *International-* or *National-Level Athletes* that is not an *International Event*.

**National-Level Athlete:** *Athletes* who compete in sport at the national level, as defined by each *National Anti-Doping Organization*, consistent with the International Standard for Testing and Investigations.

**National Olympic Committee (NOC):** The organization recognized by the International Olympic Committee. The term *National Olympic Committee* shall also include the National Sport Confederation in those countries where the National Sport Confederation assumes typical *National Olympic Committee* responsibilities in the anti-doping area.

**Out-of-Competition:** Any period which is not *In-Competition*.

**Person:** A natural *Person* or an organization or other entity.

**Prohibited List:** The List identifying the *Prohibited Substances* and *Prohibited Methods*.

**Prohibited Method:** Any method so described on the *Prohibited List*.

**Prohibited Substance:** Any substance, or class of substances, so described on the *Prohibited List*.

**Registered Testing Pool (RTP):** The pool of highest-priority *Athletes* established separately at the international level by International Federations and at the national level by *National Anti-Doping Organizations*, who are subject to focused *In-Competition* and *Out-of-Competition Testing* as part of that International Federation's or *National Anti-Doping Organization's* test distribution plan and therefore are required to provide whereabouts information as provided in Article 5.6 and the International Standard for Testing and Investigations.

**Sample or Specimen:** Any biological material collected for the purposes of *Doping Control*.

*[Comment to Sample or Specimen: It has sometimes been claimed that the collection of blood Samples violates the tenets of certain religious or cultural groups. It has been determined that there is no basis for any such claim.]*

**Tampering:** Altering for an improper purpose or in an improper way; bringing improper influence to bear; interfering improperly; obstructing, misleading or engaging in any fraudulent conduct to alter results or prevent normal procedures from occurring.

**Target Testing:** Selection of specific *Athletes* for *Testing* based on criteria set forth in the International Standard for Testing and Investigations.

**Testing:** The parts of the *Doping Control* process involving test distribution planning, *Sample* collection, *Sample* handling, and *Sample* transport to the laboratory.

**Use:** The utilization, application, ingestion, injection or consumption by any means whatsoever of any *Prohibited Substance* or *Prohibited Method*.

**WADA:** The World Anti-Doping Agency.

## 2.5.2 *ISTI* Defined Terms

**Athlete Biological Passport Documentation Package:** The material produced by the Laboratory and Athlete Passport Management Unit to support an Adverse Passport Finding such as, but not limited to, analytical data, Expert Panel comments, evidence of confounding factors as well as other relevant supporting information.

**Blood Collection Officer (BCO):** An official who is qualified to and has been authorized by the Sample Collection Authority to collect a blood *Sample* from an *Athlete*.

**Chain of Custody:** The sequence of individuals or organizations who have responsibility for the custody of a *Sample* from the provision of the *Sample* until the *Sample* has been delivered to the laboratory for analysis.

**Doping Control Officer (DCO):** An official who has been trained and authorized by the Sample Collection Authority to carry out the responsibilities given to DCOs in the International Standard for Testing and Investigations.

**Doping Control Station:** The location where the Sample Collection Session will be conducted.

**No Advance Notice Testing:** *Sample* collection that takes place with no advance warning to the *Athlete* and where the *Athlete* is continuously chaperoned from the moment of notification through *Sample* provision.

**Passport:** A collation in *ADAMS* of all relevant data unique to an individual *Athlete* that include longitudinal profiles of *Markers*, the APMU Report, heterogeneous factors unique to that particular *Athlete* and other relevant information that may help in the evaluation of *Markers*.

**Passport Custodian:** The *Anti-Doping Organization* responsible for result management of that *Athlete's Passport* and for sharing any relevant information associated to that *Athlete's Passport* with other *Anti-Doping Organization(s)*.

**Random Selection:** Selection of *Athletes* for *Testing* which is not *Target Testing*.

**Sample Collection Authority:** The organisation that is responsible for the collection of *Samples* in compliance with the requirements of the International Standard for Testing and Investigations, whether (1) the Testing Authority itself; or (2) another organization (for example, a third party contractor) to whom the Testing Authority has delegated or sub-contracted such responsibility (provided that the Testing Authority always remains ultimately responsible under the *Code* for compliance with the requirements of the International Standard for Testing and Investigations relating to collection of *Samples*).

**Sample Collection Equipment:** A and B bottles, kits or containers, collection vessels, tubes or other apparatus used to collect, hold or store the *Sample* at any time during and after the Sample Collection Session that shall meet the requirements of Article 6.3.4.

**Sample Collection Personnel:** A collective term for qualified officials authorized by the Sample Collection Authority to carry out or assist with duties during the Sample Collection Session.

**Sample Collection Session:** All of the sequential activities that directly involve the *Athlete* from the point that initial contact is made until the *Athlete* leaves the Doping Control Station after having provided his/her *Sample(s)*.

**Test Distribution Plan (TDP):** A document written by an *Anti-Doping Organization* that plans *Testing* on *Athletes* over whom it has Testing Authority, in accordance with the requirements of Article 4 of the International Standard for Testing and Investigations.

**Testing Authority:** The organization that has authorized a particular *Sample* collection, whether (1) an *Anti-Doping Organization* (for example, the International Olympic Committee or other *Major Event Organization*, WADA, an International Federation, or a *National Anti-Doping Organization*); or (2) another organization conducting *Testing* pursuant to the authority of and in accordance with the rules of the *Anti-Doping Organization* (for example, a National Federation that is a member of an International Federation).

### 2.5.3 ISL Defined Terms

**Adaptive Model:** A mathematical model that was designed to identify unusual longitudinal results from *Athletes*. The model calculates the probability of a longitudinal profile of *Marker* values assuming that the *Athlete* has a normal physiological condition.

**Aliquot**: A portion of the *Sample* of biological fluid or tissue (e.g. urine, blood) obtained from the *Athlete* used in the analytical process.

**Analytical Testing**: The parts of the *Doping Control* process involving *Sample* handling, analysis and reporting following receipt in the Laboratory.

**Athlete Passport Management Unit (APMU)**: A unit composed of a *Person* or *Persons*, designated by the *Anti-Doping Organization*, responsible for the administrative management of the Passports in *ADAMS*, advising the *Anti-Doping Organization* for intelligent, *Targeted Testing* through the APMU Report, liaising with the Expert panel, compiling and authorizing an Athlete Biological Passport Documentation Package and reporting *Adverse Passport Findings*.

**Confirmation Procedure**: An analytical test procedure whose purpose is to identify the presence or to measure the concentration/ratio of one or more specific *Prohibited Substances*, *Metabolite(s)* of a *Prohibited Substance*, or *Marker(s)* of the *Use of a Prohibited Substance* or *Method* in a *Sample*.

*[Comment: A Confirmation Procedure for a threshold substance shall also indicate a concentration/ratio of the Prohibited Substance greater than the applicable Decision Limit (as noted in the TD DL).]*

**Fit(ness)-for-purpose**: suitable for the intended purpose and compliant to the ISO/IEC 17025 or 15189, ISL and applicable technical documents.

**Initial Testing Procedure**: An analytical test procedure whose purpose is to identify those *Samples* which may contain a *Prohibited Substance*, *Metabolite(s)* of a *Prohibited Substance*, or *Marker(s)* of the *Use of a Prohibited Substance* or *Prohibited Method* or the quantity of a *Prohibited Substance*, *Metabolite(s)* of a *Prohibited Substance*, or *Marker(s)* of the *Use of a Prohibited Substance* or *Prohibited Method*.

**International Standard for Laboratories (ISL)**: The International Standard applicable to Laboratories as set forth herein.

**Laboratory(ies)**: *WADA*-accredited laboratory(ies) applying test methods and processes to provide evidentiary data for the detection of *Prohibited Substances*, *Methods* or *Markers* on the *Prohibited List* and, if applicable, quantification of a Threshold Substance in *Samples* of urine and other biological matrices in the context of anti-doping activities.

**Laboratory Documentation Packages**: The material produced by the Laboratory to support an analytical result such as an *Adverse Analytical Finding* as set forth in the *WADA* Technical Document for Laboratory Documentation Packages.

**WADA-Approved Laboratory for the ABP**: Laboratory(ies) not otherwise accredited by *WADA*; applying test methods and processes in support of an *Athlete Biological Passport* program and in accordance with the criteria for approval of non-accredited laboratories for the *Athlete Biological Passport*.

## 2.5.4 ISPPPI Defined Terms

**Anti-Doping Activities**: Activities specified by the *Code* and the *International Standards* to be carried out by *Anti-Doping Organizations*, and their Third-Party Agents, for the purpose of establishing whether anti-doping rule violations took place, including collecting whereabouts information; conducting *Testing*; performing results management; determining whether an *Athlete's Use of a Prohibited Substance or Prohibited Method* is strictly limited to legitimate and documented therapeutic purposes; educating *Participants* on their rights and responsibilities; conducting investigations into anti-doping rule violations; and initiating legal proceedings against those who are alleged to have committed such a violation.

**Personal Information**: Information, including without limitation Sensitive Personal Information, relating to an identified or identifiable *Participant* or relating to other *Persons* whose information is Processed solely in the context of an *Anti-Doping Organization's Anti-Doping Activities*.

*[3.2 Comment: It is understood that Personal Information includes, but is not limited to, information relating to an Athlete's name, date of birth, contact details and sporting affiliations, whereabouts, designated therapeutic use exemptions (if any), anti-doping test results, and results management (including disciplinary hearings, appeals and sanctions). Personal Information also includes personal details and contact information relating to other Persons, such as medical professionals and other Persons working with, treating or assisting an Athlete in the context of Anti-Doping Activities. Such information remains Personal Information and is regulated by this Standard for the entire duration of its Processing, irrespective of whether the relevant individual remains involved in organized sport.]*

**Processing (and its cognates, Process and Processed)**: Collecting, retaining, storing, disclosing, transferring, transmitting, amending, deleting or otherwise making use of Personal Information.

**Security Breach**: Any unauthorized and/or unlawful Processing of, including access to, Personal Information whether in electronic or hard-copy or other form, or interference with an information system, that compromises the privacy, security, confidentiality or integrity of Personal Information.

**Third Party**: Any natural *Person* or legal entity other than the natural *Person* to whom the relevant Personal Information relates, *Anti-Doping Organizations* and Third-Party Agents.

## 2.5.5 ABP Operating Guidelines and Related TDs Defined Terms

**APMU Report**: A report maintained by the Athlete Passport Management Unit, available in the *Athlete's Passport* in *ADAMS*, that provides a comprehensive

summary of the Expert(s) review(s) and recommendations for effective and appropriate follow-up *Testing* by the Passport Custodian.

**Expert:** The Expert(s), and/or Expert panel, with knowledge in the concerned field, chosen by the *Anti-Doping Organization* and/or Athlete Passport Management Unit, are responsible for providing an evaluation of the Passport. The Expert must be external to the *Anti-Doping Organization*. For the Haematological Module, the Expert panel should consist of at least three (3) Experts who have qualifications in one or more of the fields of clinical and laboratory haematology, sports medicine and exercise physiology, as they apply to blood doping. For the Steroidal Module, the Expert panel should be composed of at least three (3) individuals with qualifications in the fields of Laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology. For both modules, an Expert panel should consist of Experts with complementary knowledge such that all relevant fields are represented. The Expert panel may include a pool of at least three appointed Experts and any additional ad hoc Expert(s) who may be required upon request of any of the appointed Experts or by the Athlete Passport Management Unit of the *Anti-Doping Organization*.

---

## Part Three: Mandatory Protocols

### 3.0 Scope

*ADOs* implementing an *ABP* Program shall follow mandatory protocols documented in Annexes of the *International Standard for Testing and Investigations (ISTI)*. Included herein for the ease of reference, these requirements have been established to harmonize the results of monitored biological *Markers* within the *ABP* to ensure both legal fortitude and scientific certainty. This standardization of procedure allows for the sharing and mutual recognition of Passport data between the anti-doping programs of multiple *ADOs*. Only programs that fully adhere to these protocols and fully utilize *ADAMS* can be considered *ABP* Programs. These protocols are linked to Technical Documents (TDs) that a *Laboratory* or WADA-Approved Laboratory for the ABP shall follow for the analysis of *Samples* collected within the framework of the *ABP* (TDs included herein for the sake of completeness).

Section 3.1 sets out the minimum requirements for *Sample* collection and *Sample* transport that an *ADO* shall fulfil to run the Haematological Module of the *ABP* program (Annex K - *ISTI*). Sections 3.2 and 3.3 are TDs intended for *Laboratory* personnel that aim to harmonize the analysis of blood or urine *Samples* collected for the measurement of the *Markers* of the Haematological and Steroidal Modules of the *ABP*. Section 3.4 sets out the requirements and procedures that the Passport Custodian and its APMU shall follow for Result Management for the *ABP* (Annex L - *ISTI*). Finally, Section 3.5 outlines the requirements and procedures for APMUs.

## 3.1 Collection, Storage and Transport of *ABP* Blood Samples (ISTI Annex K)

### K.1 Objective

To collect an *Athlete's* blood *Sample*, intended for use in connection with the measurement of individual *Athlete* blood variables within the framework of the *Athlete Biological Passport* program, in a manner appropriate for such use.

### K.2 Requirements

K.2.1 If collection occurs after training or *Competition*, test planning shall consider the *Athlete's* whereabouts information to ensure *Testing* does not occur within two hours of such activity. If the *Athlete* has trained or competed less than two hours before the time the *Athlete* has been notified of his/her selection, the DCO or other designated Sample Collection Personnel shall chaperone the *Athlete* until this two-hour period has elapsed.

If the *Sample* was collected within two hours of training or *Competition*, the nature, duration and intensity of the exertion shall be recorded by the DCO to make this information available to the APMU and subsequently to the Experts.

K.2.2 Although a single blood *Sample* is sufficient within the framework of the *ABP*, it is recommended to collect an additional "B" *Sample* for a possible subsequent analysis of *Prohibited Substances* and *Methods* in whole blood (e.g. detection of Homologous Blood Transfusion (HBT), and/or Erythropoiesis Stimulating Agents (ESAs)).

For *Out-of-Competition Testing*, "A" and "B" urine *Samples* should be collected together with the blood *Sample(s)* in order to permit Analytical Testing for ESAs unless otherwise justified by a specific intelligent *Testing* strategy.

*[Comment: WADA's Blood Sample Collection Guidelines reflect these protocols and include practical information on the integration of ABP Testing into "traditional" Testing activities. A table has been included within the Blood Sample Collection Guidelines that identifies which particular timelines for delivery are appropriate when combining particular test types (i.e. ABP + Growth Hormone (GH), ABP + HBT, etc.), and which types of Samples may be suited for simultaneous transport.]*

K.2.3 The *Sample* shall be refrigerated from its collection until its analysis with the exception of when the *Sample* is analyzed at the collection site without delay. The storage procedure is the DCO's responsibility.

The storage and transport device shall be capable of maintaining blood *Samples* at a cool temperature during storage. Whole blood *Samples* shall not be allowed to freeze at any time. In choosing the storage and transport device, the DCO shall take into account the time of storage, the number of *Samples* to be stored in the device and the prevailing environmental conditions (hot or cold temperatures). The storage device shall be:

- a) Refrigerator.
- b) Insulated cool box.
- c) Isotherm bag.
- d) Any other device that possesses the capabilities mentioned below.

K.2.4 A temperature data logger shall be used to record the temperature from the collection to the analysis of the *Sample* except when the *Sample* is analyzed at the collection site without delay. The temperature data logger shall be able to:

- a) record the temperature in degrees Celsius at least once per minute;
- b) record time in GMT;
- c) report the temperature profile over time in text format with one line per measurement following the format "YYYY-MM-DD HH:MM T";
- d) have a unique ID of at least six characters.

K.2.5 Following notification to the *Athlete* that he/she has been selected for *Doping Control*, and following the DCO/BCO's explanation of the *Athlete's* rights and responsibilities in the *Doping Control* process, the DCO/BCO shall ask the *Athlete* to remain in a normal seated position with feet on the floor for at least 10 minutes prior to providing a blood *Sample*.

*[Comment: the Athlete shall not stand up at any time during the 10 minutes prior to Sample collection. To have the Athlete seated during 10 minutes in a waiting room and then to call the Athlete into a blood collection room is not acceptable.]*

K.2.6 In addition to a regular *Doping Control* form, the DCO/BCO shall use the *ABP* Supplementary Form if such a form is available. If an *ABP*-specific *Doping Control* form is unavailable, the DCO/BCO shall still use a regular *Doping Control* form but he/she shall collect and record the following additional information on a related form or supplementary report to be signed by the *Athlete* and the DCO/BCO:

- a) Confirm that there was no training or *Competition* in the two hours prior to the blood test.

- b) Did the *Athlete* train, compete or reside at an altitude greater than 1,500 meters within the prior two weeks? If so, or if in doubt, the name and location of the place where the *Athlete* had been and the duration of his/her stay shall be recorded. The estimated altitude shall be entered, if known.
- c) Did the *Athlete* use any form of altitude simulation such as a hypoxic tent, mask, etc. during the prior two weeks? If so, as much information as possible on the type of device and the manner in which it was used (e.g. frequency, duration, intensity) should be recorded.
- d) Did the *Athlete* receive any blood transfusion(s) during the prior three months? Was there any blood loss due to accident, pathology or donation in the prior three months? What was the estimated volume?
- e) The DCO/BCO should record on the *Doping Control* form any extreme environmental conditions the *Athlete* was exposed to during the last two hours prior to blood collection, including any sessions in any artificial heat environment, such as a sauna.
- f) Was the *Sample* collected immediately following at least three consecutive days of an intensive endurance *Competition*, such as a stage race in cycling?

K.2.7 The DCO/BCO shall start the temperature data logger and place it in the storage device. It is important to start recording the temperature before *Sample* collection.

The storage device shall be located in Doping Control Station and shall be kept secured appropriately in accordance with the *ISTI*.

K.2.8 The DCO/BCO instructs the *Athlete* to select the Sample Collection Equipment in accordance with *ISTI* Article E.4.6. If Vacutainer®(s) are not pre-labelled, the DCO/BCO shall label them with a unique *Sample* code number prior to the blood being drawn and the *Athlete* shall check that the code numbers match.

### **K.3 The *Sample* Collection Procedure**

The *Sample* collection procedure for the collection of blood for the purposes of the *ABP* is consistent with the procedure set out in *ISTI* Articles E.4, with the following additional elements:

- a) The BCO ensures that the 10-minute (or more) seated period has elapsed prior to performing venipuncture and drawing blood; and
- b) The BCO ensures that the vacuum tubes were filled appropriately; and
- c) After the blood flow into the tube ceases, the BCO removes the tube from the holder and homogenizes the blood in the tube manually by inverting the tube gently at least three times.

K.3.1 The *Athlete* and the DCO/BCO sign the *Doping Control* and *ABP* supplementary form(s), when applicable.

The blood *Sample* is sealed and deposited in the storage device next to the temperature data logger.

#### K.4 Transportation Requirements

Blood *Samples* shall be transported in a device that maintains the integrity of *Samples* over time, due to changes in external temperature.

The transport procedure is the DCO's responsibility. The transport device shall be transported by secure means using an *ADO*-authorized transport method.

The integrity of the *Markers* used in the haematological module of the *ABP* is guaranteed when the Blood Stability Score (BSS) remains below 85, where the BSS is computed as:

$$\text{BSS} = 3 * \text{T} + \text{CAT}$$

With CAT being the Collection to Analysis Time (in hours), and T the average Temperature (in degrees Celsius) measured by the data logger between *Sample* collection and analysis.

Within the framework of the BSS, the following table can be used by the DCO/BCO to estimate the maximal transport time to a Laboratory or WADA-Approved Laboratory for the ABP, called the Collection to Reception Time (CRT), for a given average temperature T:

T [°C]	CRT [h]
15	35
12	41
10	46
9	48
8	50
7	53
6	55
5	58
4	60

The DCO/BCO shall apply a conservative approach and rapidly transport the *Sample* to a Laboratory or WADA-Approved Laboratory for the ABP located close to the *Sample* collection site.

K.4.1 The DCO, BCO or other Sample Collection Personnel shall report without delay into *ADAMS*:

- a) The *Doping Control* form;
- b) The *ABP* Supplementary form, and/or the additional information specific to the *ABP* collected on a related form or supplementary report;
- c) In the Chain of Custody, the temperature data logger ID (without any time reference) and the time zone of the *Testing* location in GMT.

## 3.2 Blood Analytical Requirements for the Athlete Biological Passport

### WADA Technical Document – TD2019BAR

Document Number:	TD2019BAR	Version Number:	1.0
Written by:	WADA	Approved by:	WADA Executive Committee
Date:	16 May 2019	Effective Date:	01 June 2019

### 1. Introduction

This Technical Document (TD) has been established to harmonize the analysis of blood *Samples* collected, both *In-Competition* and *Out-of-Competition*, for the measurement of individual *Athlete* blood *Markers* within the framework of the *Athlete Biological Passport (ABP)*.

The International Standard for Laboratories (ISL) is applicable to the analysis of blood *Samples* carried out in connection with the measurement of individual *Athlete* blood *Markers* within the framework of the *ABP*. This TD describes certain specificities of blood analysis related to the *ABP*.

To standardize analytical results in the *ABP* framework, blood *Samples* shall only be analyzed with analyzers of comparable technical characteristics in the dedicated network of laboratories (*i.e.* *WADA*-accredited or WADA-Approved Laboratories for the ABP). The Analytical Method shall be included within the laboratory's ISO/IEC (17025 or 15189) scope of accreditation, and the laboratories shall participate in the *WADA External Quality Assessment Scheme (EQAS)* for blood samples prior to analysis of *Samples*.

If not reasonably possible for blood *Samples* to be analyzed in a Laboratory or WADA-Approved Laboratory for the ABP for technical and/or geographical reasons, blood *Samples* can be analyzed at a satellite facility of a Laboratory or using mobile units operated by a Laboratory under applicable ISO/IEC accreditation (17025 or 15189). Satellite facilities and mobile units shall also be ISO/IEC (17025 or 15189) accredited and participate in the *WADA EQAS* for blood samples prior to analysis of *Samples*. *Sample* handling shall be conducted in compliance with the TD on Laboratory Internal Chain of Custody (TD LCOC).

## 2. **Sample Reception and Timing of Analysis**

The blood *Sample* shall be analyzed as soon as possible upon reception and no later than 12 hours after *Sample* reception unless the Sample Collection Authority (SCA) provides specific information regarding the *Sample* collection and transportation conditions (for example, the SCA provides a projected time window for analysis during which the projected Blood Stability Score would remain acceptable) that would allow the Laboratory or WADA-Approved Laboratory for the ABP to extend the time window of the analysis of the *Sample* without compromising *Sample* validity.

In cases when the Laboratory or WADA-Approved Laboratory for the ABP is unable to analyze the *Sample* immediately after reception, the Laboratory or WADA-Approved Laboratory for the ABP is responsible for maintaining the *Sample* at a cool temperature (approximately 4°C) between reception and the start of the Analytical Testing procedure. The temperature data logger shall accompany the *Sample* until *Sample* homogenization. The blood *Sample* shall not be aliquoted before *ABP* analysis, however the *Sample* may be aliquoted after the *ABP* analysis has been satisfactorily completed, when appropriate (*e.g.* for the performance of other analyses such as for homologous blood transfusion or agents affecting erythropoiesis).

If there is a Laboratory or WADA-Approved Laboratory for the ABP deviation from the aforementioned procedure, the Laboratory or WADA-Approved Laboratory for the ABP shall proceed with the analysis and report the results into *ADAMS* with a detailed description of the deviation. If the *Sample* cannot be analyzed, the Laboratory or WADA-Approved Laboratory for the ABP shall report the *Sample* as “Not Analyzed” and provide a description of why it could not be analyzed in *ADAMS*.

## 3. **Instrument Check**

The Laboratory or WADA-Approved Laboratory for the ABP shall maintain an instrument maintenance schedule to ensure proper performance; particularly if an analysis has not been recently conducted and the instrument remains idle for an extended period of time.

The analyst shall ensure that all reagents are within their expiration dates and comply with the reagent manufacturer’s recommendations before performing an analysis. Operational parameters of the instrument (background level, temperature of the incubation chambers, pressure, etc.) shall be verified as compliant with manufacturer’s specifications.

All internal quality controls (levels 1, 2 and 3) shall be analyzed twice, following the specifications provided by the manufacturer, prior to the analysis of *Samples*. All results relevant to the *ABP* shall be in agreement with the reference value ranges of the manufacturer. These internal quality controls shall be furnished exclusively by

the instrument manufacturer and handled in strict accordance with the manufacturer specifications (*e.g.* expiration dates, storage conditions). The analysis of internal quality controls shall be monitored via quality control charts with appropriate control limits.

At least one internal quality control from the manufacturer (either level 1, 2 or 3) shall be analyzed after every 30 to 50 blood *Samples*. At the end of each analysis session and after all blood *Sample* analyses are completed, one internal quality control (either level 1, 2 or 3) shall be analyzed once again to demonstrate the continuous stability of the instrument and the quality of the analyses done.

At least once a month, following the satisfactory analysis of all internal quality controls (levels 1, 2 and 3) as described above, one fresh blood *Sample* shall be homogenized for a minimum period of 15 minutes on an appropriate mixer (*e.g.* roller mixer) and analyzed at least seven (7) consecutive times under Repeatability conditions. The Repeatability of the determinations, expressed as coefficients of variation (CV %), shall be below 1.5 % for Haemoglobin (HGB) and Haematocrit (HCT), and below 15 % for Reticulocyte percentage (RET%).

#### **4. External Quality Assessment Scheme (EQAS)**

The Laboratories or WADA-Approved Laboratories for the ABP shall participate in and meet the requirements of WADA's EQAS for blood *Markers* for the *ABP*. WADA's EQAS program is the only EQAS relevant to the Laboratory's or WADA-Approved Laboratory for the ABP's compliance with the requirements for the analysis of blood *Markers* within the framework of the *ABP* (in case of discrepancy with other blood EQAS programs).

All internal quality controls (levels 1, 2 and 3) shall be analyzed twice following the specifications provided by the manufacturer prior to the analysis of EQAS samples. All results relevant to the *ABP* shall be in agreement with the reference value ranges of the manufacturer. The EQAS sample shall be homogenized for a minimum period of 15 minutes using an appropriate mixer (*e.g.* roller mixer) prior to analysis. The external quality controls shall be analyzed multiple times consecutively (based on the EQAS rules), and the mean results of the following blood variables (full blood count) shall be returned:

Red Blood Cell (Erythrocyte) Count	RBC
Mean Corpuscular Volume	MCV
Haematocrit	HCT
Haemoglobin	HGB
Mean Corpuscular Haemoglobin	MCH
Mean Corpuscular Haemoglobin Concentration	MCHC
White Blood Cell (Leukocyte) Count	WBC

Platelet (Thrombocyte) Count	PLT
Reticulocytes Percentage	RET%

Laboratories or WADA-Approved Laboratory for the ABP may also participate in ring tests between laboratories (hospitals, clinics, etc.) using the same technology and the same procedure.

## 5. Analysis of Blood Samples

5.1 The temperature data logger shall be stopped before *Sample* homogenization, upon removal of the blood *Samples* from the cooling device or refrigerator. The blood *Sample* shall be homogenized for a minimum period of 15 minutes using an appropriate mixer (*e.g.* roller mixer) prior to analysis.

In cases when the temperature data logger accompanies multiple *Samples*, and these *Samples* are analyzed in the same batch by the Laboratory, the temperature data logger shall be stopped before the homogenization of the first *Sample*. The Laboratory shall proceed with the analysis of all *Samples* associated to the temperature data logger without delay.

5.2 The blood *Sample* shall be analyzed twice and the Laboratory's procedure should minimize the delay between the two analyses. Absolute differences between the two (2) analyses shall be equal or less ( $\leq$ ) than each of the following criteria in order to accept the results:

- 0.1 g/dL for HGB;
- 0.15 % for RET% if either the first or second measurement is lower or equal to 1.00 %; otherwise 0.25 % absolute difference.

The data from the second injection is used to confirm the first injection data. Therefore, if the absolute differences between the results of the analyses are within the criteria above, then only the first injection data is reported into *ADAMS*.

If the absolute differences between the results of the two analyses are greater than those defined above, then the blood *Sample* shall be analyzed twice again in accordance with section 5.2. In cases of repeated analysis of a *Sample*, the *Sample* shall be mixed prior to re-analysis using the automated mixing feature of the blood analyzer or by appropriate manual inversion. This reanalysis procedure shall be repeated until the absolute differences between the results of the two (2) most recent analyses are within the criteria specified above.

The requirements for an Initial Testing Procedure, an "A" Sample Confirmation Procedure and a "B" Sample Confirmation Procedure, as defined in the ISL, shall not be applicable to blood *Samples* analyzed for the purposes of the *ABP*.

## 6. Reporting

The Laboratory or WADA-Approved Laboratory for the ABP shall promptly report into *ADAMS* the raw temperature profile recorded by the temperature data logger. The filename shall consist in the concatenation of the data logger ID with the date of *Sample* reception by the lab (“YYYY-MM-DD” in local time) separated by an underscore. For example, for a data logger ID “KG34V10” and a date of *Sample* reception “2015-03-25”, the Laboratory or WADA-Approved Laboratory for the ABP shall report the temperature profile under the filename “KG34V10\_2015-03-25.txt”. The Laboratory or WADA-Approved Laboratory for the ABP shall report the temperature profile before the test results of the *Sample*.

The Laboratory or WADA-Approved Laboratory for the ABP shall report the following into *ADAMS*:

- Status (“Submitted” or “Not Analyzed”);
- *Sample* code;
- Type of test (*Out-of-Competition* / *In-Competition*);
- Sport and discipline;
- Date and time of receipt of the *Sample*;
- Date and time of analysis of the *Sample*;
- The name of the Testing Authority;
- The name of the Sample Collection Authority;
- Type of *Sample* (blood Passport);
- Type of analyzer;
- Test results (other variables may be included for quality purposes):

Blood Variable		Unit(s)
Haemoglobin	HGB	g/dL
Hematocrit	HCT	%
Immature Reticulocyte Fraction	IRF	%
Mean Corpuscular Haemoglobin	MCH	pg
Mean Corpuscular Haemoglobin Concentration	MCHC	g/dL
Mean Corpuscular Volume	MCV	fL
OFF-Score	-	-
Platelets	PLT	10 <sup>3</sup> /uL
Red Blood Cell Distribution Width	RDW-SD	fL
Red Blood Cells	RBC	10 <sup>6</sup> /uL
Reticulocytes – in absolute number	RET	10 <sup>6</sup> /uL
Reticulocytes Percentage	RET%	%
White Blood Cells	WBC	10 <sup>3</sup> /uL

- Include a comment describing any relevant deviation as part of the *Sample's* *ADAMS* record.

### 3.3 Endogenous Anabolic Androgenic Steroids Measurement and Reporting

#### WADA Technical Document – TD2018EAAS

Document Number:	TD2018EAAS	Version Number:	1.0
Written by:	WADA Laboratory Expert Group	Approved by:	WADA Executive Committee
Date:	16 May 2018	Effective Date:	1 September 2018

#### 1.0 Introduction

The purpose of this Technical Document (TD) is to harmonize the approaches to the measurement and reporting of Endogenous Anabolic Androgenic Steroids (EAAS) in urine *Samples*, including data in support of the steroidal module of the *Athlete Biological Passport (ABP)* (the steroidal Passport).

EAAS concentrations and their ratios form the urinary “steroid profile”, which may be altered following the administration of synthetic forms of EAAS, in particular testosterone (T), its precursors [for example androstenediol, androstenedione and prasterone (dehydroepiandrosterone or DHEA)], or its active metabolite [dihydrotestosterone (DHT)], as well as epitestosterone (E).

The steroidal module of the *ABP* utilizes the Adaptive Model to identify an *Atypical Passport Finding (ATPF)*, which triggers the performance of Confirmation Procedures. It is also useful for intelligent longitudinal *Target Testing* of an *Athlete*. Furthermore, an abnormal “steroid profile” (obtained from a single urine *Sample*) or an atypical steroidal Passport (including “steroid profiles” obtained from a series of *Samples* collected over a period of time), may be used as a means to pursue an anti-doping rule violation (ADRV).

EAAS Analytical Testing and reporting follows a two-step procedure. An Initial Testing Procedure is conducted to estimate the “steroid profile” of the *Athlete’s Sample*. A subsequent Confirmation Procedure is performed when the estimated “steroid profile” constitutes an *ATPF*, as determined by the Adaptive Model, or represents a “suspicious steroid profile” (SSP) finding, or upon request from the Athlete Passport Management Unit (APMU), the Testing Authority or *WADA*.

The Confirmation Procedure includes the quantification of the *Markers* of the “steroid profile” as described in this TD as well as Gas Chromatography – Combustion - Isotope Ratio Mass Spectrometry (GC/C/IRMS) analysis, which is considered in a separate TD (TD IRMS) [1].

## 1.1 The "Steroid Profile"

Each urine *Sample* shall be analyzed to determine its "steroid profile".

For the purposes of this TD, the "steroid profile" is composed of the following *Markers* (as free steroid content obtained from the free steroid fraction plus those released from the conjugated fraction after hydrolysis with  $\beta$ -glucuronidase from *E. coli*):

- Androsterone (A)
- Etiocholanolone (Etio)
- 5 $\alpha$ -Androstane-3 $\alpha$ ,17 $\beta$ -diol (5 $\alpha$ Adiol)
- 5 $\beta$ -Androstane-3 $\alpha$ ,17 $\beta$ -diol (5 $\beta$ Adiol)
- Testosterone (T)
- Epitestosterone (E).

and the following ratios:

- T/E
- A/T
- A/Etio
- 5 $\alpha$ Adiol/5 $\beta$ Adiol
- 5 $\alpha$ Adiol/E.

The administration of EAAS can alter one or more of the *Markers* and/or ratios of the urinary "steroid profile", resulting in increase or decrease of concentrations and/or ratios of specific pairs of steroid *Metabolites* [2-4].

Additionally, alteration of the urinary "steroid profile" can occur for a number of reasons including, but not limited to, the following confounding factors:

- the administration of other anabolic steroids (*e.g.* stanozolol);
- the administration of human chorionic gonadotrophin (hCG) in males;
- the administration of aromatase inhibitors and anti-estrogens;
- the administration of inhibitors of 5 $\alpha$ -reductase (*e.g.* finasteride);
- intake of alcohol (ethanol);
- the administration of ketoconazole or other similar compounds;
- the use of masking agents (*e.g.* probenecid) and diuretics; or
- microbial growth.

## 2.0 Initial Testing Procedure

The Laboratory shall use a validated Initial Testing Procedure that is Fit-for-Purpose to estimate the *Markers* of the urinary “steroid profile” in the range of values determined in males and females.

The Initial Testing Procedure is conducted on a single Aliquot.

### 2.1 Method Characteristics

- Gas chromatography combined with mass spectrometry (GC-MS or GC-MS/MS) of TMS derivatives (keto- and hydroxyl- groups) is required;
- Calibration standard(s) or a calibration curve should be included in each sequence of analysis;
- At least two urine quality control (QC) samples containing varying and representative concentrations of the *Markers* of the “steroid profile” should be included in each sequence of analysis;
- The enzymatic hydrolysis shall be carried out with purified  $\beta$ -glucuronidase from *E. coli* (*H. pomatia* mixtures are not acceptable);
- The completeness of hydrolysis of the glucuroconjugated urinary steroids shall be controlled with isotopically labeled A-glucuronide (or an equivalent scientifically recognized alternative);
- The completeness of the derivatization shall be controlled through the monitoring of mono-O-TMS vs. di-O-TMS derivative of A;
- When needed, the volume<sup>1</sup> of the *Sample Aliquot* may be adjusted as a function of its specific gravity (SG) and of the sex of the *Athlete*;
- The T/E ratios shall be determined from the ratios of the corrected chromatographic peak areas or peak heights<sup>2</sup>;
- The linearity of the method, established during method validation, shall cover the ranges of *Marker* concentrations normally found in males and females -

---

<sup>1</sup> Much smaller concentrations of T and E are generally present in *Samples* from females and in those *Samples* with low SG; therefore, larger Aliquot volumes may be required for a reliable measurement.

<sup>2</sup> Ratios of T and E peak heights or peak areas corrected against a calibrator or a calibration curve (same mass or same ion transition screened for both steroids).

the limit of quantification (LOQ) for T and E shall not be greater than 2 ng/mL<sup>2</sup>;

- The relative standard combined Measurement Uncertainty [ $u_c$  (%)] for the determination of A, Etio, 5 $\alpha$ Adiol, 5 $\beta$ Adiol, T and E, as estimated during method validation of the Initial Testing Procedure, shall be:
  - Not greater than 30% at the respective LOQ;
  - Not greater than 20% (for A and Etio) or 25% (for the Adiols) at five (5) times the LOQ;
  - Not greater than 20% (for T and E) when the concentration is greater than 5 ng/mL.
- The  $u_c$  (%) for determinations of T/E ratios calculated from the corrected chromatographic peak areas or heights shall be:
  - Not greater than 15% when the concentrations of T and E are both greater (>) than 5 ng/mL;
  - Not greater than 30% when the concentrations of T and/or E are equal to or lower ( $\leq$ ) than 5 ng/mL.
- Evidence of microbial degradation [*e.g.* presence of indicators of 3 $\alpha$ -hydroxysteroid dehydrogenase (HSD) activity] and the presence of 5 $\alpha$ -reductase inhibitors (*e.g.* finasteride), ethanol *Metabolite(s)* and ketoconazole (and similar substances) shall be monitored by the Laboratory<sup>3</sup>.

---

<sup>2</sup> The LOQ for the "steroid profile" *Markers* shall be determined as the lowest concentration that can be measured within a  $u_c$  (%) of 30%.

The LOQ determined from the method validation of T, E, A, Etio, 5 $\alpha$ Adiol and 5 $\beta$ Adiol shall be recorded in *ADAMS* by the Laboratory. The LOQ values shall be updated in *ADAMS* whenever a significant change is made to the analytical method.

<sup>3</sup> The direct enzymatic hydrolysis of urine *Samples* may increase the effects of microbial contamination.

## 2.2. Reporting the "steroid profile" from the Initial Testing Procedure

Following the performance of the Initial Testing Procedure, the Laboratory shall report in *ADAMS* the "steroid profile" for each *Sample* analyzed<sup>4, 5</sup>, including:

- the SG<sup>6</sup> of the *Sample*;
- the concentrations of T, E, A, Etio, 5 $\alpha$ Adiol and 5 $\beta$ Adiol<sup>7, 8, 9</sup>;

---

<sup>4</sup> This also applies when more than one (1) *Sample* from the same *Athlete*, which are linked to a single Sample Collection Session, are analyzed.

<sup>5</sup> The Laboratory shall report in *ADAMS* the *Sample's* "steroid profile", as determined during the Initial Testing Procedure, in cases when no *Prohibited Substance* or *Prohibited Method* is detected in the *Sample* [while reporting the test result as a Negative Finding], as well as in cases when the Laboratory confirms the presence of a *Prohibited Substance* or *Prohibited Method* [while reporting the result as an *Adverse Analytical Finding (AAF)* or *Atypical Finding (ATF)*, as applicable, for the *Prohibited Substance* or *Prohibited Method* detected].

<sup>6</sup> As determined by the Laboratory using, for example, a refractometer.

<sup>7</sup> When reporting the "steroid profile" in *ADAMS*, the Laboratory shall report the values of concentrations for T, E, A, Etio, 5 $\alpha$ Adiol and 5 $\beta$ Adiol, and the T/E ratio (**without adjustment for the urine SG or correction to a specific number of significant figures**). An automatic correction of reported values to 2 significant figures will be made in *ADAMS* upon application of the Adaptive Model of the *ABP*.

<sup>8</sup> When the Initial Testing Procedure measurement of a "steroid profile" *Marker* is not possible due to, for example, dilution, unusual matrix interferences, inhibition of the enzymatic hydrolysis or incomplete derivatization, the Laboratory should repeat the analysis with an alternative, validated *Sample* preparation procedure (*e.g.* concentrating the *Sample* or taking larger Aliquot volumes, application of solid phase extraction, extraction with a different solvent or other equivalent procedure). If, however, the *Marker* of the "steroid profile" cannot be quantified, the concentration of the *Marker* shall be reported as "-1". When the chromatographic peak signal for a *Marker* cannot be detected (*i.e.* is below the detection capability of the assay), the concentration of the *Marker* shall be reported as "-2" (see Table 1).

<sup>9</sup> The Laboratory may also provide information on other steroidal parameters such as dehydroepiandrosterone (DHEA) and 6 $\alpha$ -hydroxy-androstenedione at the request of the Testing Authority, Results Management Authority or the APMU.

- the T/E ratio<sup>2, 10</sup>;
- signs of microbial activity in the *Sample*, e.g. ratios of 5 $\alpha$ -androstanedione (5 $\alpha$ AND) to A and 5 $\beta$ -androstanedione (5 $\beta$ AND) to Etio<sup>11</sup>;
- the presence or absence in the *Sample* of substance(s) that may alter the “steroid profile”<sup>12</sup>.

In cases when a *Sample* is not consistent with human urine (e.g. SG  $\leq$  1.001, creatinine  $\leq$  5 mg/dL [5], non-physiological salt concentration, abnormal pH values, absence or abnormally low levels of endogenous steroids, corticosteroids, proteins), the Laboratory shall:

- report the finding as an AAF for *Tampering* or *Attempted Tampering* (class M2.1 of the *Prohibited List*) if the Laboratory can unequivocally identify the nature of the liquid (e.g. water, liquor, synthetic urine) provided as the adulterated *Sample*; or
- report the finding as an AAF for *Tampering* or *Attempted Tampering* if the Laboratory has reason to believe that the *Sample* could have been altered in any manner, improperly interfered with, or potentially been the subject of any fraudulent conduct that could alter the results of Analytical Testing; or
- inform the Testing Authority about the suspicious finding and request further information which may support the reporting of this finding as an AAF for *Tampering* or *Attempted Tampering* (e.g. longitudinal “steroid profile” data for the *Athlete*); or
- report the finding as an ATF for *Tampering* or *Attempted Tampering* and include a comment in *ADAMS* advising the Testing Authority to perform further investigations (e.g. additional analyses on the *Sample*, *Target Testing* the *Athlete*) in order to establish whether *Tampering* of the *Sample* has occurred and the finding be treated as an Anti-Doping Rule Violation.

---

<sup>10</sup> The values of A/T, A/Etio, 5 $\alpha$ Adiol/5 $\beta$ Adiol and 5 $\alpha$ Adiol/E ratios are automatically computed in *ADAMS* after the reporting of the “steroid profile” by the Laboratory.

<sup>11</sup> A *Sample* showing signs of microbial degradation or containing any of the substances that may cause an alteration of the “steroid profile” (see section 1.1) may not be suitable for inclusion in the “longitudinal steroid profile”. These findings are to be considered by the APMU during the results management process when evaluating the analytical data for the *Sample* and assessing the possible pathological or confounding conditions that may have impacted the *Sample's* “steroid profile”.

### 2.2.1 Validity of (the “steroid profile” of) the *Sample*

The validity of the *Sample* will be determined automatically upon reporting the “steroid profile” in *ADAMS* in accordance to:

a) **“Invalid”**: only when the *Sample* shows signs of extensive degradation<sup>12</sup>, as determined by:

- $5\alpha\text{AND}/\text{A} \geq 0.1$ , and/or
- $5\beta\text{AND}/\text{Etio} \geq 0.1$

b) **“Valid”**: in all other situations, including:

- $\text{LOD} \leq [\text{T and/or E}] < \text{LOQ}$

When the concentration of either T and/or E in the *Sample Aliquot* analyzed cannot be quantified, but its chromatographic peak signal is still detectable (e.g.  $\text{S/N} > 3$ ) and the T/E ratio can be determined from the corrected chromatographic peak areas or peak heights<sup>2</sup>, the calculated value of the T/E ratio shall be reported in *ADAMS*, whereas the concentration of T and/or E, as applicable, shall be reported as “-1” (Table 1)<sup>9</sup>.

- $[\text{T}] < \text{LOD}$

If the chromatographic peak signal for T cannot be detected, the concentration of T shall be reported as “-2” and the T/E value shall be reported as “-1” (Table 1)<sup>9</sup> and:

- i. for  $[\text{E}] \geq \text{LOQ}$ , a comment shall be included in *ADAMS* stating that the T/E ratio could not be measured because the concentration of T was below the detection capability of the assay; or
- ii. for  $\text{LOD} \leq [\text{E}] < \text{LOQ}$ , the concentration of E shall be reported as “-1”<sup>9</sup> and a comment shall be included in *ADAMS* stating that the T/E ratio could not be measured because the concentrations of T and E could not be measured.

---

<sup>12</sup> In addition, following the reporting of the “steroid profile” in *ADAMS* by the Laboratory, the *Sample* may be evaluated as “invalid” by the APMU upon review of the “steroid profile” data, for example, by considering the presence of substances that may alter the “steroid profile” in the *Sample*.

- [E] < LOD

If the chromatographic peak signal for E cannot be detected, the concentration of E shall be reported as “-2”<sup>9</sup> (Table 1) and:

- for [T] ≥ LOQ, the T/E ratio shall be calculated on the basis of the Laboratory’s LOD value for E (*e.g.* if T concentration is 3 ng/mL and E cannot be detected, and the Laboratory’s LOD for E is 0.5 ng/mL, the T/E shall be reported as 6.0) (Table 1). A comment shall be included in *ADAMS* stating that the T/E ratio could not be measured accurately because the concentration of E was below the detection capability of the assay; or
- for  $\text{LOD} \leq [\text{T}] < \text{LOQ}$ , the T/E ratio and the concentration of T shall be reported as “-1”<sup>9</sup> and a comment shall be included in *ADAMS* stating that the T/E ratio could not be measured accurately because the concentrations of T and E could not be measured (Table 1).

- Both [T and E] < LOD:

If the chromatographic peak signals for both T and E cannot be detected, the concentrations of T and E shall be reported as “-2” and the T/E value shall be reported as “-2” (Table 1)<sup>9</sup>. A comment shall be included in *ADAMS* stating that the T/E ratio could not be measured because the concentrations of both T and E were below the detection capability of the assay.

- When other *Marker(s)* of the “steroid profile” cannot be measured accurately:

- $\text{LOD} \leq [\text{Marker}] < \text{LOQ}$

If the concentration of the *Marker* in the Aliquot is below the LOQ of the assay, but its chromatographic peak signal is still detectable (*i.e.* above the LOD of the assay), the concentration of the *Marker* shall be reported as “-1”<sup>9</sup>.

- [Marker] < LOD

If the chromatographic peak signal for the *Marker* cannot be detected (*i.e.* below the LOD of the assay), the concentration shall be reported as “-2”<sup>9</sup>.

- When less extensive microbial contamination is detected which shall be reported in *ADAMS*<sup>12</sup> as:

5 $\alpha$ AND/A ratio and/or 5 $\beta$ AND/Etio ratio between 0.05 and 0.1.

- When the Laboratory reports an *AAF* or an *ATF* for a *Prohibited Substance* that may alter the “steroid profile” (*e.g.* an anabolic steroid, hCG in males, a diuretic or masking agent)<sup>12</sup>;
- When the Laboratory detects and reports the presence in the *Sample* of other substances that may cause an alteration of the “steroid profile” (see section 1.1)<sup>12, 13</sup>.

---

<sup>13</sup> It is mandatory that the Laboratory tests at least for the presence of conjugated *Metabolite(s)* of ethanol [*e.g.* ethanol glucuronide (EtG)], inhibitors of 5 $\alpha$ -reductase and ketoconazole during the Initial Testing Procedure and report the estimated concentration of EtG if above 5  $\mu\text{g}/\text{mL}$  (without the need to report the Measurement Uncertainty).

**Table 1.** Summary of conditions for reporting T and E concentrations and T/E ratio.

Concentration of T	Concentration of E	T/E ratio
Chromatographic peak signal of T measured at or above the LOQ.  $[T] \geq LOQ_{(T)}$  <b>Report T as measured</b>	Chromatographic peak signal of E measured at or above LOQ.  $[E] \geq LOQ_{(E)}$ <b>Report E as measured.</b>	<b>Report T/E as determined</b> from corrected peak heights/areas
	Chromatographic peak signal of E detected, but below LOQ.  $LOD_{(E)} \leq [E] < LOQ_{(E)}$ <b>Report E as “-1”<sup>9</sup></b>	
	Chromatographic peak signal of E not detected.  $[E] < LOD_{(E)}$ <b>Report E as “-2”<sup>9</sup></b>	<b>Report T/E as T/LOD<sub>(E)</sub></b> <i>Comment in ADAMS:</i> T/E ratio could not be measured accurately because the concentration of E was below the detection capability of the assay
Chromatographic peak signal of T detected, but below the LOQ.  $LOD_{(T)} \leq [T] < LOQ_{(T)}$  <b>Report T as “-1”<sup>9</sup></b>	Chromatographic peak signal of E measured at or above LOQ.  $[E] \geq LOQ_{(E)}$ <b>Report E as measured</b>	<b>Report T/E as measured</b> from corrected peak heights/areas
	Chromatographic peak signal of E detected, but below LOQ.  $LOD_{(E)} \leq [E] < LOQ_{(E)}$ <b>Report E as “-1”<sup>9</sup></b>	
	Chromatographic peak signal of E not detected.  $[E] < LOD_{(E)}$ <b>Report E as “-2”<sup>9</sup></b>	<b>Report T/E as “-1”</b> <i>Comment in ADAMS:</i> T/E ratio could not be measured accurately because the concentrations of T and E could not be measured
Chromatographic peak signal of T not detected.  $[T] < LOD_{(T)}$  <b>Report T as “-2”<sup>9</sup></b>	Chromatographic peak signal of E measured at or above LOQ.  $[E] \geq LOQ_{(E)}$ <b>Report E as measured</b>	<b>Report T/E as “-1”</b> <i>Comment in ADAMS:</i> T/E ratio could not be measured because the concentration of T was below the detection capability of the assay
	Chromatographic peak signal of E detected but below LOQ.  $LOD_{(E)} \leq [E] < LOQ_{(E)}$ <b>Report E as “-1”<sup>9</sup></b>	<b>Report T/E as “-1”</b> <i>Comment in ADAMS:</i> T/E ratio could not be measured because the concentrations of T and E could not be measured
	Chromatographic peak signal of E not detected.  $[E] < LOD_{(E)}$ <b>Report E as “-2”<sup>9</sup></b>	<b>Report T/E as “-2”</b> <i>Comment in ADAMS:</i> T/E ratio could not be measured because the concentrations of both T and E were below the detection capability of the assay

### 3.0 Confirmation Procedures

Confirmation Procedures for the exogenous administration of EAAS include the GC-MS or GC-MS/MS quantification<sup>14</sup> and GC/C/IRMS analysis of the *Marker(s)* of the "steroid profile".

In addition, the Laboratory shall confirm the presence or absence, as applicable, of the confounding factors of the "steroid profile" as described in section 1.1, *i.e.* conjugated *Metabolite(s)* of ethanol (*e.g.* EtG), inhibitors of 5 $\alpha$ -reductase (*e.g.* finasteride), ketoconazole as well as the signs of microbial degradation including, for example, the presence of the free forms of T, 5 $\alpha$ AND or 5 $\beta$ AND.

#### 3.1 "Atypical Passport Finding Confirmation Procedure Request (ATPF-CPR)"

Following the Laboratory's reporting of a *Sample's* "steroid profile" in ADAMS, the *Sample* record is matched with a Doping Control Form (DCF), which allows the inclusion of the *Sample's* "steroid profile" in the *Athlete's* steroidal Passport in ADAMS.

The Adaptive Model will generate an "ATPF-CPR" notification when the *Sample's* T/E ratio is abnormally high, as determined by the Adaptive Model, when compared with the previous longitudinal T/E values of the *Athlete*.

The Laboratory shall proceed with the Confirmation Procedures when receiving an "ATPF-CPR" notification for the *Sample*, except in the following cases:

- If the APMU advises the Laboratory, in writing, not to confirm the "steroid profile" of the *Sample* based on justifiable reason(s). Justification for not proceeding with a Confirmation Procedure for an *ATPF* may include:
  - the presence of EtG in a *Sample* from an *Athlete* with previous similar findings in his/her Passport with negative GC/C/IRMS results (indicating a pattern of alcohol abuse); or
  - if other *AAFs* have been reported for the *Sample*, which would likely lead to a maximum sanction.

---

<sup>14</sup> For T/E values, only T needs to be confirmed if the concentration levels of E or the volume of the *Sample* is not sufficient.

In such cases, the Laboratory shall update the *ADAMS* report for the *Sample* with a comment stating that the APMU requested not to perform the Confirmation Procedure(s). The APMU shall also update the APMU Report in *ADAMS* with an explanation of why the Confirmation Procedure(s) were not necessary.

- In addition, the GC/C/IRMS Confirmation Procedure for an *ATPF* is not mandatory if the GC-MS or GC-MS/MS quantitative analysis does not confirm the abnormally high T/E ratio of the *Sample* (see section 3.5 below). In such cases, the Laboratory shall report the confirmed values of the *Markers* of the “steroid profile” in *ADAMS* (see section 3.6 below) with a comment stating that the GC/C/IRMS analysis was not performed because the abnormally high T/E ratio was not confirmed.

The Adaptive Model will also determine abnormal values of the other ratios of the “steroid profile” (A/T, A/Etio, 5 $\alpha$ Adiol/5 $\beta$ Adiol, 5 $\alpha$ Adiol/E). However, in such cases the Laboratory will not receive an automatic “*ATPF-CPR*” notification through *ADAMS*. Instead, the Athlete Passport Management Unit (APMU) will advise the Testing Authority on whether the *Sample* shall be subjected to Confirmation Procedures. Therefore, in these cases the Laboratory shall receive a request from the Testing Authority before proceeding with the Confirmation Procedure(s)<sup>15</sup>.

### 3.2 “Suspicious Steroid Profile Confirmation Procedure Request (SSP-CPR)”

The Laboratory will receive a “SSP-CPR” notification through *ADAMS* if:

- 1) The *Sample* is matched with a DCF in *ADAMS*, but there is no existing steroidal Passport of the *Athlete* in *ADAMS* (*i.e.* this is the first *Sample* in the *Athlete’s* steroidal Passport), or

The *Sample* cannot be matched with a DCF in *ADAMS* within fourteen (14) calendar days after the reception date of the *Sample* by the Laboratory, and therefore the “steroid profile” of the *Sample* cannot be processed by the Adaptive Model in *ADAMS*,

and

---

<sup>15</sup> Unless covered by an agreement between the Laboratory and the Testing Authority.

2) The *Sample's* "steroid profile" meets **any** of the following criteria:

- T/E ratio (calculated from the corrected chromatographic peak areas or heights) greater than 4.0;
  - A/T ratio less than 20;
  - $5\alpha$ Adiol/ $5\beta$ Adiol ratio greater than 2.4;
  - concentration of T or E (adjusted for the  $SG^{7, 16}$ ) greater than 200 ng/mL in males or greater than 50 ng/mL in females;
  - concentration of A or Etio (adjusted for the  $SG^{7, 17}$ ) greater than 10,000 ng/mL;
  - concentration of  $5\alpha$ Adiol (adjusted for the  $SG^{7, 17}$ ) greater than 250 ng/mL in males or greater than 150 ng/mL in females, combined with a  $5\alpha$ Adiol/E ratio greater than 10 in either sex.
- Upon receipt of the "SSP-CPR" notification, the Laboratory shall proceed with the Confirmation Procedure(s) unless, after contacting the Testing Authority, the Testing Authority can justify in writing within seven (7) calendar days that the Confirmation Procedure(s) is not necessary. Justification for not proceeding with the Confirmation Procedure may include, for example, a naturally elevated T/E ratio confirmed by previous Analytical Testing, or a T/E ratio between 4.0 and 6.0 for the first test on the *Athlete*, or if other *AAFs* have been reported for the *Sample*, which would likely lead to a maximum sanction;
  - If the Testing Authority justifies that confirmation is not necessary, the Laboratory shall update the *ADAMS* report for the *Sample* with a comment stating that the Testing Authority considered that the Confirmation Procedure(s) was not necessary and detail the explanation provided by the Testing Authority. If the Testing Authority does not justify that confirmation is not necessary, the Laboratory shall proceed with the confirmation analyses.

---

<sup>16</sup> The concentrations are adjusted to a urine  $SG^7$  of 1.020 based on the following equation (free and hydrolyzed glucuroconjugated steroids).

$$\text{Conc}_{\text{corr}} = \text{Conc}_{\text{measured}} * (1.020 - 1) / (SG - 1)$$

In cases when the Laboratory receives "ATPF-CPR" or "SSP-CPR" for two (2) or more *Samples*, which are linked to a single *Sample* collection session from the same *Athlete*, the Laboratory, in consultation with the Testing Authority, shall prioritize the confirmation of the *Sample* with the highest concentration levels of the *Markers* of the "steroid profile".

When the Laboratory receives an "ATPF-CPR" or a "SSP-CPR" for a *Sample* for which *AAF(s)* have been reported for other *Prohibited Substance(s)* or *Method(s)*, the Laboratory should consult the Testing Authority about the need to conduct the Confirmation Procedures for the *Markers* of the "steroid profile".

### 3.3 Confirmation Procedure Requests from the APMU, the Testing Authority or WADA.

Confirmation Procedures for the "steroid profile" may be also performed on *Samples* at the request of the APMU, the Testing Authority or *WADA*.

In addition, a Laboratory may have a contractual agreement in place with the Testing Authority to conduct the Confirmation Procedures when a *Sample* meets any of the analytical criteria of a "suspicious steroid profile" or at the Laboratory's discretion based on its expertise. In such circumstances, the Laboratory may proceed to the confirmation of the "suspicious steroid profile" immediately without waiting for an "ATPF-CPR" or a "SSP-CPR" through *ADAMS*.

### 3.4 GC-MS or GC-MS/MS quantification Confirmation Procedure

The Laboratory shall identify (in compliance with the TD IDCR [6]) and quantify all the *Markers* of the "steroid profile" in one additional *Sample Aliquot* by a validated Fit-for-Purpose GC-MS or GC-MS/MS quantification method.

The Laboratory shall confirm quantitatively all the *Markers* of the "steroid profile" before proceeding with the GC/C/IRMS analysis.

#### 3.4.1 Method Characteristics for the GC-MS or GC-MS/MS quantification Confirmation Procedure

The same analytical requirements presented in section 2.1 shall apply, with the following modifications:

- A Solid Phase Extraction (SPE) shall be performed prior to the enzymatic hydrolysis of the *Sample*;
- Calibration standards and urine QC samples containing representative levels of the *Markers* of the "steroid profile" shall be included;
- The  $u_c$  (%) shall be not greater than 15% for determinations of A, Etio, 5 $\alpha$ Adiol and 5 $\beta$ Adiol at concentrations representing five times the respective LOQ;

- For determinations of T, E and T/E ratios, the  $u_c$  (%) shall be not greater than 15% when the concentrations of T and E are greater than 5 ng/mL.

### 3.5 GC/C/IRMS Confirmation Procedure

Technical and reporting requirements for the GC/C/IRMS Confirmation Procedure are specified in the TD IRMS [1].

- In the case of an *ATPF-CPR*, GC/C/IRMS analysis is not mandatory when the confirmed T/E value is below the confirmation T/E threshold calculated by the Adaptive Model and provided within the *ATPF-CPR* notification received from *ADAMS*;
- For other Confirmation Procedure requests (*i.e.* SSP-CPR or upon APMU/Testing Authority/WADA request), when the quantitative GC-MS or GC-MS/MS Confirmation Procedure does not confirm the values reported from the Initial Testing Procedure (taking into consideration the expanded uncertainty of the measurement), the Laboratory shall consult the Testing Authority to determine if the GC/C/IRMS analysis is necessary. In such cases, the Testing Authority shall consult with the APMU of the Passport Custodian in order to assess whether the GC/C/IRMS analysis is still necessary. In the event that GC/C/IRMS analysis is deemed unnecessary, the Laboratory shall update the *ADAMS* report for the *Sample* with the newly confirmed values of the "steroid profile" and include a comment that GC/C/IRMS analysis was not necessary. The APMU shall also update the APMU Report in *ADAMS* with an explanation of why the GC/C/IRMS Confirmation Procedure was not necessary.

### 3.6 Reporting Results from the Confirmation Procedures

Following the performance of the Confirmation Procedure(s) on the "A" or the "B" *Sample*<sup>17</sup>, the Laboratory shall report in *ADAMS*:

- the SG<sup>7</sup> of the *Sample* (determined from a new Aliquot of the "A" or "B" *Sample*, as applicable);
- the confirmed values (*e.g.* concentrations, T/E ratio) of the *Markers* of the "steroid profile", without adjustment for the SG of the *Sample*<sup>8, 9, 11</sup>;
- the associated  $u_c$  expressed in units;
- the GC/C/IRMS confirmation results, if determined (see section 3.5 and TD IRMS [1]);
- the confirmed results for signs of microbial contamination (*e.g.* 5 $\alpha$ AND/A, 5 $\beta$ AND/Etio, T<sub>free</sub> / T<sub>total</sub><sup>18</sup>);
- the confirmed presence or absence of conjugated *Metabolite(s)* of ethanol, inhibitors of 5 $\alpha$ -reductase (*e.g.* finasteride), ketoconazole or any other substances that might have altered the "steroid profile", if applicable. The Laboratory shall report the confirmed estimated levels of EtG if above 5  $\mu$ g/mL (without the need to report the Measurement Uncertainty for this determination).

Following the confirmation of the "steroid profile", the Laboratory shall update the *ADAMS* test result record for the *Sample* (as *AAF*, *ATF*, or "Negative") based on the results of the GC/C/IRMS Confirmation Procedure, if performed, in accordance with the TD IRMS [1]).

---

<sup>17</sup> When an *AAF* is reported for the *Marker(s)* of the "steroid profile" based on the results of a GC/C/IRMS analysis performed on the "A" *Sample*, only the GC/C/IRMS analysis shall be repeated during the "B" *Sample* Confirmation Procedure, if applicable. Refer to the TD IRMS [1].

<sup>18</sup> In addition to the determination of the 5 $\alpha$ AND/A and 5 $\beta$ AND/Etio ratios as signs of microbial contamination, as described in section 2.2.1 for the Initial Testing Procedure, the determination during the Confirmation Procedure of an elevated ratio of free Testosterone to total Testosterone (T<sub>free</sub> / T<sub>total</sub> > 0.05) will also invalidate (the "steroid profile" of) the *Sample*.

### 3.7 Additional Analyses: Steroid Ester(s) and DNA

When matched blood *Samples* have been collected during the same Sample Collection Session as urine *Samples* identified with an atypical or suspicious “steroid profile”, Laboratories, in consultation with the Testing Authority, should consider conducting analysis to detect the presence of steroid ester(s) in the associated serum/plasma.

It is recommended that confirmation analyses for steroid ester(s) in serum/plasma be conducted prior to the performance of the GC/C/IRMS analysis in urine. The detection of steroid ester(s) in serum/plasma also constitutes an unequivocal demonstration of the exogenous origin of the steroid(s). On the other hand, the absence of detectable steroid ester(s) in serum/plasma shall not invalidate an *AAF* based on the GC/C/IRMS analysis in urine.

The performance of a DNA analysis may also be considered to establish, in conjunction with the *Athlete's* “longitudinal steroid profile”, the origin of the *Sample(s)*.

## 4.0 References

1. WADA Technical Document TD IRMS (current version): Detection of synthetic forms of Endogenous Anabolic Androgenic Steroids by GC/C/IRMS.  
[https://www.wada-ama.org/en/resources/search?ff\[0\]=field\\_resource\\_collections%3A30](https://www.wada-ama.org/en/resources/search?ff[0]=field_resource_collections%3A30)
2. Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W. Factors influencing the steroid profile in doping control analysis. *J Mass Spectrom.* **43**(7):877-91, 2008.
3. Ayotte C. Detecting the administration of endogenous anabolic androgenic steroids. *Handb Exp Pharmacol.* **195**:77-98, 2010.
4. Kuuranne T, Saugy M, Baume N. Confounding factors and genetic polymorphism in the evaluation of individual steroid profiling. *Br J Sports Med.* **48**(10):848-55, 2014.
5. J D Cook, Caplan YH, LoDico CP and Bush DM. The Characterization of Human Urine for Specimen Validity Determination in Workplace Drug Testing: A Review. *J Anal Toxicol* **24**: 579-588, 2000
6. WADA Technical Document TDIDCR (current version): Minimum Criteria for Chromatographic-Mass Spectrometric Confirmation of the Identity of Analytes for Doping Control Purposes.  
[https://www.wada-ama.org/en/resources/search?ff\[0\]=field\\_resource\\_collections%3A30](https://www.wada-ama.org/en/resources/search?ff[0]=field_resource_collections%3A30)

## 3.4 Results Management Requirements and Procedures for the Athlete Biological Passport (ISTI Annex L)

### L.1 Administrative Management

L.1.1 The requirements and procedures described in this Annex apply to all modules of the *Athlete Biological Passport (ABP)* except where expressly stated or implied by the context.

L.1.2 These processes shall be administered and managed by an Athlete Passport Management Unit (APMU) on behalf of the Passport Custodian. The APMU will initially review profiles to facilitate targeting recommendations for the Passport Custodian when appropriate or refer to the Experts as required. Management and communication of the biological data, APMU reporting and Expert reviews shall be recorded in *ADAMS* and be shared by the Passport Custodian with other *Anti-Doping Organizations (ADOs)* with *Testing* jurisdiction over the *Athlete* to coordinate further Passport Testing as appropriate. A key element for *ABP* management and communication is the APMU Report in *ADAMS* which provides an overview of the current status of the *Athlete's Passport* including the latest targeting recommendations and a summary of the Expert reviews.

L.1.3 This Annex describes a step-by-step approach to the review of an *Athlete's Passport*:

- a) The review begins with the application of the Adaptive Model.
- b) In case of an *Atypical Passport Finding (ATPF)* or when the APMU considers that a review is otherwise justified, an Expert conducts an initial review and returns an evaluation based on the information available at that time.
- c) In case of a "Likely doping" initial review, the Passport is then subjected to a review by three Experts including the Expert who conducted the initial review.
- d) In case of a "Likely doping" consensus of the three Experts, the process continues with the creation of an ABP Documentation Package.
- e) An *Adverse Passport Finding (APF)* is reported by the APMU to the Passport Custodian if the Experts' opinion is maintained after review of all information available at that stage, including the ABP Documentation Package.
- f) The *Athlete* is notified of the *Adverse Passport Finding (APF)* and offered the opportunity to provide explanations.

- g) If after review of the explanations provided by the *Athlete*, the Experts maintain their unanimous conclusion that it is highly likely that the *Athlete* used a *Prohibited Substance* or a *Prohibited Method*, an anti-doping rule violation (ADRV) is asserted against the *Athlete* by the Passport Custodian and disciplinary proceedings are initiated (Code Article 7.5).

*[Comment: The ABP follows a similar logical structure to results management for analytical Testing, with both processes culminating in a possible ADRV based on, respectively, Code Article 2.2 and Code Article 2.1. An ATPF is to the ABP what an Atypical Finding (ATF) is to analytical Testing; both require further investigation. Similarly, an APF is to the ABP what the Adverse Analytical Finding (AAF) is to analytical Testing; both require results management in accordance with Code Article 7.]*

## L.2 Initial Review Phase

### L.2.1 Review by the Adaptive Model

L.2.1.1 In *ADAMS*, the Adaptive Model automatically processes biological *Markers* of the *ABP*. These *Markers* include primary *Markers* that are defined as the most specific to doping and secondary *Markers* that provide supporting evidence of doping in isolation or in combination with other *Markers*. The Adaptive Model predicts for an individual an expected range within which a series of *Marker* values falls assuming a normal physiological condition. Outliers correspond to those values outside of the 99%-range, from a lower limit corresponding to the 0.5<sup>th</sup> percentile to an upper limit corresponding to the 99.5<sup>th</sup> percentile (1:100 chance or less that this result is due to normal physiological variation). A specificity of 99% is used to identify both haematological and steroidal *ATPFs*. In the case of sequence deviations (sequence *ATPFs*), the applied specificity is 99.9% (1:1000 chance or less that this is due to normal physiological variation).

L.2.1.2 An *ATPF* is a result generated by the Adaptive Model in *ADAMS* which identifies either a primary *Marker(s)* value(s) as being outside the *Athlete's* intra-individual range or a longitudinal profile of a primary *Marker* values (sequence deviations) as being outside expected ranges, assuming a normal physiological condition. An *ATPF* requires further attention and review.

L.2.1.3 The APMU may also submit a Passport to the Expert when there is no *ATPF* (see L.2.2.4 below).

#### L.2.1.4 *ATPF* – Haematological Module

L.2.1.4.1 For the Haematological Module, the Adaptive Model automatically processes in *ADAMS* two primary *Markers*, haemoglobin concentration (HGB) and stimulation index OFF-score (OFFS), and two secondary *Markers*, the reticulocyte percentage (RET%) and the Abnormal Blood Profile Score (ABPS). An *ATPF* is generated when a HGB and/or OFFS value of the last test falls outside the expected intra-individual ranges. Furthermore, the longitudinal profile composed of (up to) the last 5 valid HGB and/or OFFS values is also considered as an *ATPF* when deviating from the expected ranges, as determined by the Adaptive Model (sequence *ATPF*). An *ATPF* is only generated by the Adaptive Model based on values of the primary *Markers* HGB and OFFS or the sequence thereof.

L.2.1.4.2 In case of an *ATPF* the APMU shall advise the Testing Authority in the APMU Report, or via the Passport Custodian where appropriate, on whether the *Sample*, or any accompanying urine *Sample*, should be subjected to analysis for Erythropoietic Stimulating Agents (ESAs). The APMU should also provide recommendations for ESA analysis when the Adaptive Model detects an abnormality in the secondary *Markers* RET% and/or ABPS.

#### L.2.1.5 *ATPF* – Steroidal Module

L.2.1.5.1 For the Steroidal Module, the Adaptive Model automatically processes in *ADAMS* one primary *Marker*, the T/E ratio, and four secondary *Markers*, the ratios A/T, A/Etio, 5 $\alpha$ Adiol/5 $\beta$ Adiol and 5 $\alpha$ Adiol/E.

L.2.1.5.2 Ratios coming from a *Sample* that showed signs of heavy microbial degradation, and ratios for which one or both of the concentrations were not measured accurately by the Laboratory as established in the Technical Document for Endogenous Anabolic Androgenic Steroids (TDEAAS), shall not be processed by the Adaptive Model. In the case where the Laboratory reports a factor that may otherwise cause an alteration in the steroid profile, such as the presence of ethanol glucuronide in the *Sample*, the APMU shall evaluate whether the steroid profile can still be processed by the Adaptive Model and the *Sample* be subjected to a Confirmation Procedure (see TDEAAS).

L.2.1.5.3 An *ATPF* is generated when a value of the T/E ratio falls outside the expected intra-individual ranges. In addition, the “longitudinal steroid profile” composed of (up to) the last 5 valid values of the T/E ratio is also considered as atypical when deviating from the expected ranges, as determined by the Adaptive Model (sequence *ATPF*).

L.2.1.5.4 In the case of a longitudinal steroidal profile, an *ATPF* caused by an atypically high T/E value will trigger an *ATPF Confirmation Procedure* Request notification through *ADAMS* as established in the TDEAAS. When the Adaptive Model

determines an abnormality in any of the other ratios of the “steroid profile” (A/T, A/Etio, 5 $\alpha$ Adiol/5 $\beta$ Adiol, 5 $\alpha$ Adiol/E), the APMU should advise the Testing Authority in the APMU Report, or via the Passport Custodian where appropriate, on whether the Sample should be subjected to a Confirmation Procedure.

#### L.2.1.6 Departure from *WADA ABP* requirements

L.2.1.6.1 If there is a departure from *WADA ABP* requirements for Sample collection, transport and analysis, the biological Marker result obtained from this Sample affected by the non-conformity shall not be considered in the Adaptive Model calculations (for example, RET% can be affected but not HGB under certain transportation conditions).

L.2.1.6.2 A Marker result which is not affected by the non-conformity can still be considered in the Adaptive Model calculations. In such case, the APMU shall provide the specific explanations supporting the inclusion of the result(s). In all cases, the Sample shall remain recorded in the Athlete’s Passport. The Experts may include all results in their review provided that their conclusions may be validly supported when taking into account the effects of the non-conformity.

#### L.2.2 The Initial Expert Review

L.2.2.1 A Passport generating an ATPF, or for which a review is otherwise justified, shall be sent by the APMU to an Expert for review in *ADAMS*. This should take place within seven working days following the generation of the ATPF in *ADAMS*. The review of the Passport shall be conducted based on the Passport and other basic information (e.g. competition schedules), which may be available, such that the Expert is blinded to the identity of the Athlete.

*[Comment to L.2.2.1: If a result rendered by a Laboratory represents an ATPF caused by an atypically high T/E value, the Sample will undergo a Confirmation Procedure, including GC-C-IRMS analysis. If the result of the GC-C-IRMS Confirmation Procedure is negative or inconclusive then the APMU shall seek an Expert review. An APMU or Expert review is not required when the GC-C-IRMS Confirmation Procedure renders an Adverse Analytical Finding (AAF).]*

L.2.2.2 If a Passport has been recently reviewed by an Expert and the Passport Custodian is in the process of executing a specific multi-Sample Testing strategy on the Athlete, the APMU may delay the review of a Passport generating an ATPF triggered by one of the Samples collected in this context until completion of the planned series of tests. In such situations, the APMU shall clearly indicate the reason for delaying the review of the Passport in the APMU Report.

L.2.2.3 If the first and unique result in a Passport is flagged as an *ATPF* by the Adaptive Model, the APMU may recommend the collection of an additional *Sample* before initiating the initial Expert review.

L.2.2.4 Review in the absence of an *ATPF*

L.2.2.4.1 A Passport may also be sent for Expert review in the absence of an *ATPF* where the Passport includes other elements otherwise justifying a review. These elements may include, without limitation:

- a) Data not considered in the Adaptive Model
- b) Any abnormal levels and/or variations of *Markers*
- c) Signs of hemodilution in the haematological Passport
- d) Steroid levels in urine below the corresponding limit of quantification (LOQ) of the assay
- e) Intelligence in relation to the *Athlete* concerned.

L.2.2.4.2 An Expert review initiated in the above-mentioned situations may result in the same consequences as an Expert review triggered by an *ATPF*.

L.2.2.5 Expert Evaluation

L.2.2.5.1 When evaluating a Passport, an Expert weighs the likelihood that the Passport is the result of the *Use of a Prohibited Substance or Prohibited Method* against the likelihood that the Passport is the result of a normal physiological or pathological condition in order to provide one of the following opinions: "Normal", "Suspicious", "Likely doping" or "Likely medical condition". For a "Likely doping" opinion, the Expert shall come to the conclusion that the likelihood that the Passport is the result of the *Use of a Prohibited Substance or Prohibited Method* outweighs the likelihood that the Passport is the result of a normal physiological or pathological condition.

*[Comment to L.2.2.5.1: When evaluating competing propositions, the likelihood of each proposition is evaluated by the Expert based on the evidence available for that proposition. It is acknowledged that it is the relative likelihoods (i.e., likelihood ratio) of the competing propositions that ultimately determine the Expert's opinion. For example, where the Expert is of the view that a Passport is highly likely the result of the *Use of a Prohibited Substance or Prohibited Method*, it is necessary for a "Likely doping" evaluation that the Expert consider that it is unlikely that it may be the result of a normal physiological or pathological condition. Similarly, where the Expert is of the view that a Passport is likely the result of the *Use of a Prohibited Substance or Prohibited Method*, it is necessary for a*

*“Likely doping” evaluation that the Expert consider that it is highly unlikely that it may be the result of a normal physiological or pathological condition.]*

L.2.2.5.2 To reach a conclusion of “Likely doping” in the absence of an *ATPF*, the Expert shall come to the opinion that it is highly likely that the Passport is the result of the *Use of a Prohibited Substance or Prohibited Method* and that it is highly unlikely that the Passport is the result of a normal physiological or pathological condition.

### L.2.3 Consequences of the Initial Review

Depending on the outcome of the initial review, the APMU will take the following action:

<u>Expert</u> Evaluation	<u>APMU</u> Action
“Normal”	Continue normal <i>Testing</i> plan.
“Suspicious”	Provide recommendations to the <u>Passport Custodian</u> for <i>Target Testing, Sample</i> analysis and/or requesting further information as required.
“Likely doping”	Send to a panel of three <u>Experts</u> , including the initial <u>Expert</u> , as per section L.3 of this Annex L.
“Likely medical condition”	Inform the <i>Athlete</i> via the <u>Passport Custodian</u> (or send to other <u>Experts</u> ).

*[Comment to L.2.3: The ABP is a tool to detect the possible Use of Prohibited Substance(s) or Prohibited Method(s) and it is not intended as a health check or for medical monitoring. It is important that the Passport Custodian educates the Athletes to ensure that they undergo regular health monitoring and not rely on the ABP for this purpose. Nevertheless, the Passport Custodian should inform the Athlete in case the Passport indicates a likely pathology as determined by the Experts.]*

## L.3 Review by Three Experts

L.3.1 In the event that the opinion of the appointed Expert in the initial review, pending other explanation to be provided at a later stage, is that of “Likely doping”, the Passport shall then be sent by the APMU to two additional Experts for review. This should take place within seven working days after the reporting of the initial review. These additional reviews shall be conducted without knowledge of the initial review. These three Experts, now constitute the Expert panel, composed of the Expert appointed in the initial review and these two other Experts.

L.3.2 The review by the three Experts must follow the same procedure where

applicable, as presented in section L.2.2 of this Annex. The three Experts shall each provide their individual reports in *ADAMS*. This should take place within seven working days after receipt of the request.

L.3.3 The APMU is responsible for liaising with the Experts and for advising the Passport Custodian of the subsequent Expert assessment. The Experts can request further information, as they deem relevant for their review, notably information related to medical conditions, *Competition schedule* and/or *Sample(s)* analysis results. Such requests are directed via the APMU to the Passport Custodian.

L.3.4. A unanimous opinion among the three Experts is necessary in order to proceed further towards declaring an *APF*, which means that all three Experts render an opinion of “Likely doping”. The conclusion of the Experts must be reached with the three Experts assessing the *Athlete’s Passport* with the same data.

*[Comment to L.3.4: The three Expert opinions cannot be accumulated over time based on different data.]*

L.3.5 To reach a conclusion of “Likely doping” in the absence of an *ATPF*, the Expert panel shall come to the unanimous opinion that it is highly likely that the Passport is the result of the *Use of a Prohibited Substance or Method* and that there is no reasonably conceivable hypothesis under which the Passport is the result of a normal physiological condition and highly unlikely that it is the result of pathological condition.

L.3.6 In the case when two Experts evaluate the Passport as “Likely doping” and the third Expert as “Suspicious” but asking for more information, the APMU shall confer with the Expert panel before they finalize their opinion. The group can also seek advice from an appropriate outside Expert, although this must be done while maintaining strict confidentiality of the *Athlete’s* personal information.

L.3.7 If no unanimity can be reached among the three Experts, the APMU shall report the Passport as “Suspicious”, update the APMU Report, and recommend that the Passport Custodian pursue additional *Testing* and/or gather intelligence on the *Athlete* (refer to Information Gathering and Intelligence Sharing Guidelines), as appropriate.

#### **L.4 Conference Call, Compilation of the ABP Documentation Package and Joint Expert Report**

L.4.1 If a unanimous opinion of “Likely doping” is rendered by all three Experts, the APMU shall declare a “Likely doping” evaluation in the APMU Report in *ADAMS* and organize a conference call with the Expert panel to initiate the next steps for the case, including proceeding with the compilation of the ABP Documentation Package (see Technical Document for Athlete Passport Management Units) and drafting of the joint Expert report. In preparation for this conference call, the APMU should coordinate with the Passport Custodian to compile any potentially relevant information to share with the Experts (e.g. suspicious analytical findings, relevant intelligence and relevant pathophysiological information).

L.4.2 Once completed, the ABP Documentation Package shall be sent by the APMU to the Expert panel, who will review it and provide a joint Expert report to be signed by all three Experts. The conclusion within the joint Expert report shall be reached without interference from the Passport Custodian. If necessary, the Expert panel may request complementary information from the APMU.

L.4.3 At this stage, the identity of the *Athlete* is not mentioned but it is accepted that specific information provided may allow to identify the *Athlete*. This shall not affect the validity of the process.

#### **L.5 Issuing an Adverse Passport Finding (APF)**

L.5.1 If the Expert panel confirms their unanimous position of “Likely doping”, the APMU shall declare an *Adverse Passport Finding (APF)* in *ADAMS* that includes a written statement of the *APF*, the ABP Documentation Package and the joint Expert report.

L.5.2 After reviewing the ABP Documentation Package and joint Expert report, the Passport Custodian shall:

- a) Notify the *Athlete* of the *APF* and that the Passport Custodian is considering the assertion of an anti-doping rule violation (ADRV) against the *Athlete*.
- b) Provide the *Athlete* the ABP Documentation Package and the joint Expert report.
- c) Invite the *Athlete* to provide their own explanation, in a timely manner, of the data provided to the Passport Custodian.

## **L.6 Review of Explanation from Athlete and Disciplinary Proceedings**

L.6.1 Upon receipt of any explanation and supporting information from the *Athlete*, which should be received within the specified deadline, the APMU shall forward it to the Expert panel for review with any additional information that the Expert Panel considers necessary to render its opinion in coordination with both the Passport Custodian and the APMU. At this stage, the review is no longer anonymous. The Expert panel shall reassess or reassert the case and reach one of the following conclusions:

- a) Unanimous opinion of “Likely doping” by the Experts based on the information in the Passport, and any explanation provided by the *Athlete*; or
- b) Based on the available information, the Experts are unable to reach a unanimous opinion of “Likely doping” set forth above.

*[Comment to L.6.1: Such a reassessment shall also take place when the Athlete does not provide any explanation.]*

L.6.2 If the Expert panel expresses the opinion set forth in section L.6.1 a), then the Passport Custodian shall be informed by the APMU and proceed to results management (*Code* Article 7.5).

L.6.3 If the Expert panel expresses the opinion set forth in section L.6.1 b), the APMU shall update the APMU Report and recommend the Passport Custodian to pursue additional *Testing* and/or gather intelligence on the *Athlete* (refer to Information Gathering and Intelligence Sharing Guidelines), as appropriate. The Passport Custodian shall notify the *Athlete* and *WADA* of the outcome of the review.

## **L.7 Passport Re-setting**

L.7.1 In the event the *Athlete* has been found to have committed an ADRV based on the Passport, the *Athlete's* Passport shall be reset by the Passport Custodian at the start of the relevant period of *Ineligibility* and a new Biological Passport ID shall be assigned in *ADAMS*. This maintains the *Athlete's* anonymity for potential APMU and Expert panel reviews conducted in the future.

L.7.2 When an *Athlete* is found to have committed an ADRV on any basis other than the *ABP*, the Haematological and/or Steroidal Passport will remain in effect, except in those cases where the *Prohibited Substance* or *Prohibited Method* resulted in an alteration of the haematological or steroidal *Markers*, respectively (e.g. for *AAF* reported for anabolic androgenic steroids, which may affect *the Markers* of the steroid profile, or for the *Use* of ESAs or blood transfusions, which would alter the haematological *Markers*). The Passport Custodian shall consult with their APMU following an *AAF* to determine whether a Passport reset is warranted. In such instances, the *Athlete's* profile(s) would be reset from the time of the beginning of the sanction.

## 3.5 Athlete Passport Management Unit Requirements and Procedures

### WADA Technical Document – TD2019APMU

Document Number:	TD2019APMU	Version Number:	1.0
Written by:	WADA	Approved by:	WADA Executive Committee
Date:	20 September 2018	Effective Date:	01 March 2019

#### 1.0 Introduction

This Technical Document has been established to harmonize effective management of Athlete Passports by providing specific requirements that an Athlete Passport Management Unit (APMU) shall meet in order to be a WADA approved APMU.

#### 2.0 APMU Roles and Responsibilities

2.1 The APMU is the dedicated unit that is responsible for the timely management of Passports in the Anti-Doping Administration and Management System (ADAMS) on behalf of the Passport Custodian. Passport management by the APMU involves:

- a) Performing Passport assessments to make timely *Target Testing* recommendations to the *Anti-Doping Organization (ADO)* via the APMU Report in ADAMS when appropriate; and
- b) Managing the review of atypical Passports according to Annex L of the International Standard for Testing and Investigations (ISTI), including, but not limited to, the following:
  - Issuing and updating APMU Reports in ADAMS,
  - In case of an *Atypical Passport Finding (ATPF)*, or when a review is otherwise justified, assigning and liaising with the Expert panel as required,
  - Compiling all necessary information to establish an Athlete Biological Passport (ABP) Documentation Package, and
  - Declaring *Adverse Passport Findings (APFs)* to the Passport Custodian and WADA.

2.2 The APMU shall assess and manage Passport Sample validity in ADAMS, in consultation with the Experts or Laboratories when necessary per Article 8.2 of this Technical Document.

2.3 The APMU shall provide support to the Passport Custodian in defining priorities in order to optimize the efficiency of their *ABP* program. These priorities may include, but are not limited to, cost efficiency, special analyses, Test Distribution Plans, and *Target Testing*.

### 3.0 APMU Hosting

3.1 An APMU shall be hosted by a Laboratory.<sup>1</sup>

3.2 APMU hosting by a Laboratory does not preclude the use of qualified APMU managers employed by *ADOs* or other Laboratories.

3.3 Passport management shall be carried out in *ADAMS* using dedicated APMU accounts associated with the host Laboratory regardless of the physical location of the APMU manager(s).

3.4 The host Laboratory shall implement procedures to maintain the operational independence of the APMU, including the appointment of dedicated personnel with a specified time commitment to the APMU and a separate allocation in the budget so that the APMU can continue to function should the *WADA* accreditation of the Laboratory be suspended (see 0 below).

### 4.0 APMU Personnel

4.1 Personnel employed by, or under contract to, the APMU shall have a personal file which shall contain copies of the curriculum vitae or qualification form, a job description, and records of initial and ongoing training related to anti-doping. The APMU shall maintain appropriate confidentiality of Personal Information.

4.2 All personnel shall have a thorough knowledge of their responsibilities including respect of the confidentiality of results, the procedures for the management of *Sample* validity and compilation of ABP Documentation Packages, and the Passport review process.

4.3 The host Laboratory shall have a *Person* qualified to function as the designated head of the APMU<sup>2</sup> by assuming professional, organizational, educational, and administrative responsibility of the APMU. The APMU director is responsible for ensuring the APMU operates in compliance with this Technical Document and

---

<sup>1</sup> Hosting in this context is defined as the provision of facilities and resources for the efficient functioning of the APMU.

<sup>2</sup> The head of the APMU is termed "director" herein, however use of this title is not a requirement and can be adjusted according to the needs of the organization.

applicable *International Standards*. In particular, the APMU director assumes the responsibility of signing and delivering all *APFs* to the Passport Custodian and *WADA*.

The APMU director's qualifications shall ensure that he or she is competent and capable of leading the APMU operations, including:

- A doctoral degree (or equivalent) in one of the natural sciences or medicine, or in the absence of a doctoral degree, a master's degree (or equivalent) with extensive and appropriate anti-doping science experience and training (*i.e.*, minimum of five (5) years);
- Management experience;
- Ability to oversee compliance with quality management practices; and
- Good command of at least one of *WADA*'s two official languages, English and French.

It is acknowledged that the APMU director plays an essential role in the APMU operations and that *WADA* APMU approval is delivered based upon appointment of a proper candidate. *WADA* reserves the right to review the credentials of such appointment in accordance with the above qualifications.

Any personnel changes to the position of APMU director shall be communicated to *WADA* no later than one month prior to the scheduled date the APMU director vacates his/her position. A succession plan shall be submitted to *WADA*.

The APMU director is notably responsible for monitoring the quality of Passport management and ensuring that other APMU personnel have the experience and training necessary to perform their duties.

4.4 The APMU shall use qualified scientific personnel to serve as APMU manager(s)<sup>3</sup> to manage the Passport review process and *Sample* validity, and to provide *Target Testing* and Analytical Testing recommendations through APMU Reports in *ADAMS*. APMU manager(s) shall be employed by the host Laboratory or be under contract by an *ADO* or another Laboratory.<sup>4</sup> The APMU should have at least one APMU manager per Module of the *ABP*.

---

<sup>3</sup> The designation of "manager" is used herein, however use of this title is not a requirement and can be adjusted according to the needs of the organization. The APMU director can also serve in the role of APMU manager as required.

<sup>4</sup> An individual APMU manager may be contracted by multiple APMUs concurrently. Where the APMU manager is employed by an *ADO*, it is assumed that this individual will have access to the identity and other privileged or confidential information about the *Athlete*, past *Testing* and/or results management and investigations history. This additional information shall not be shared by the APMU manager in the APMU Report, but is recognized to be important to contribute to effective *Target Testing*.

APMU manager(s) shall have qualifications in one or more Modules of the *ABP*. The qualifications are at minimum:

- Bachelor's degree (or equivalent) in one of the natural or health sciences. Documented experience of three (3) years or more in anti-doping or similar scientific training is equivalent to a Bachelor's degree for this position; and
- Adequate training in one or more Modules of the *ABP*, capacity to understand and evaluate analytical results and the physiological response to the *Use of Prohibited Substances* and *Prohibited Methods*, as well as criteria relevant for *Target Testing*.

Where the APMU manager has strong qualifications in Laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology, and is not employed by the Passport Custodian, the APMU manager can act as a first Expert for the Steroidal Module of the *ABP*.

4.5 The APMU should have administrative personnel to coordinate with the Passport Custodian to compile the necessary documentation required for the ABP Documentation Packages, manage communication with various stakeholders and assist with the organization of APMU-related documentation.

## 5.0 APMU Confidentiality and Security

5.1 All APMU related activities shall be carried out in accordance with the confidentiality requirements of the *Code* and *International Standards*. Personal Information shall be maintained in strict confidence in accordance with the International Standard for the Protection of Privacy and Personal Information (ISPPPI) and applicable national and regional laws.

5.2 The APMU shall have a policy to ensure the confidentiality of its procedures and security of its information systems regardless of the physical location of the APMU personnel at the time of Passport management, such as when the APMU manager is physically located in an *ADO*, another Laboratory or when travelling.

5.3 The APMU shall have a policy for the security of its activities and information systems against unauthorized access. Such policy should be based on a threat and risk assessment by expert(s) in the relevant field.

5.4 The APMU shall adhere to those information retention times set forth in Annex A of the ISPPPI. In consultation with the Passport Custodian, the APMU shall develop specific plans and procedures to ensure the secure retention and eventual destruction of Personal Information.

## 6.0 **ABP Expert Panel**

6.1 The APMU shall engage the services of qualified Experts for the review of Passports in accordance with Annex L of the ISTI.

6.2 The APMU shall establish, in consultation with the *ADO*, a list of Experts who are qualified to comprise an Expert panel for the review of Passports for which the *ADO* is the Passport Custodian.

- For the Haematological Module, the Expert panel should consist of at least three (3) Experts who have qualifications in one or more of the fields of clinical and laboratory haematology, sports medicine and exercise physiology, as they apply to blood doping.
- For the Steroidal Module, the Expert panel should be composed of at least three (3) individuals with qualifications in the fields of Laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology.
- All three (3) Experts forming an Expert panel assigned to review a particular Passport shall not be of one and the same nationality and no two (2) Experts shall have a primary affiliation with the same organization, institution or company, including, but not limited to, universities, hospitals and research institutes.
- At least one Expert on the Expert panel shall currently serve, or have previously served as an Expert and reviewed Passports for a *WADA*-approved APMU.

6.3 The APMU shall ensure that each Expert:

- receives relevant *ABP* Expert education resources provided by *WADA*; and,
- has an Expert account created in *ADAMS* by the APMU for the anonymous review of Passports.
- is independent of the Passport Custodian and has been requested to declare all potential conflicts of interest in reviewing Passports<sup>5</sup>, and
- has signed the *WADA ABP* Expert Code of Conduct. The *ABP* Expert Code of Conduct is provided in Appendix A of this Technical Document.

---

<sup>5</sup> An APMU manager may also concurrently serve as an Expert for other APMUs, provided all requirements of Article 6.0 are met.

---

## 7.0 Process and Requirements for *WADA* APMU Approval

Passports shall only be managed by APMUs that have been approved by *WADA*.

### 7.1 Applying for *WADA* APMU Approval

#### 7.1.1 Expression of interest

The candidate APMU shall officially contact *WADA* in writing to express its interest in the *WADA* APMU approval process.

#### 7.1.2 Preliminary discussion with *WADA*

The purpose of this discussion is to clarify issues with regard to the approval process and to obtain information about different aspects of the APMU relevant to the approval process. Such a discussion could be conducted prior to or during the approval process.

#### 7.1.3 Description of the candidate APMU

The candidate APMU shall then complete a detailed application form provided by *WADA* and submit it to *WADA* no later than eight (8) weeks following receipt. The application form includes, but is not limited to, the following:

- List of staff, their qualifications and intended role within the APMU;
- Description of physical facilities, including a description of the security considerations for records and computer systems;
- List of external Experts, their contact information, and their qualifications;
- Business plan for the APMU and letters of support from *ADOs* that demonstrate a commitment to manage<sup>6</sup> a minimum of 100 haematological Passports and 500 steroidal Passports from *Code-compliant Testing Authorities* (as determined by *WADA*) annually, within one year of receiving approval. An eligible business plan shall demonstrate a commitment to provide at least 200 APMU Reports for haematological Passports and 500 APMU Reports for steroidal Passports per year.

#### 7.1.4 Liability insurance coverage

The APMU shall provide documentation to *WADA* that professional liability risk insurance coverage or equivalent has been obtained which covers the APMU to an

---

<sup>6</sup> See Article 2.0 for a description of the role of the APMU in Passport management.

---

amount of no less than 2 million USD annually, and should ensure that the Expert panel has suitable professional liability risk insurance or equivalent coverage.

#### 7.1.5 Operational independence

The APMU shall ensure a degree of operational independence from the host Laboratory such that the APMU can continue to fulfill its responsibilities in compliance with this Technical Document should the WADA accreditation of the Laboratory be suspended, where the reason for the Suspension does not have an impact on the function of the APMU. Operational independence implies that the APMU shall have a separate allocation in the budget and sufficient technical and human resources to permit the APMU to manage its own affairs without hindrance or interference by host Laboratories.

#### 7.1.6 Compliance with the WADA APMU Code of Ethics

The candidate APMU shall implement and comply with the provisions in the WADA APMU Code of Ethics (Appendix B). The APMU shall provide the APMU Code of Ethics to APMU personnel and ensure their understanding and compliance with all aspects. The candidate APMU shall provide to WADA a letter of compliance with the APMU Code of Ethics, signed by the APMU director.

#### 7.1.7 WADA recommendation for approval

After receipt of the application form, WADA will complete and submit a report to the candidate APMU. The report will include a recommendation concerning approval of the candidate APMU. In the case where the recommendation is that the APMU should not be approved, the report will identify improvements required in order to be re-considered for designation as a WADA approved APMU. In the case where the recommendation is that the APMU should be approved, the report and recommendation will be submitted to the WADA Executive Committee for approval.

#### 7.1.8 Issuing approval letter and publishing APMU list on WADA website

A letter signed by a duly authorized representative of WADA shall be issued in recognition of approval of an APMU. Such letter shall specify the name of the APMU and the period for which the approval is valid. Approval may be granted after the effective date, with retroactive effect. An updated list of approved APMUs shall be published by WADA on WADA's website.

### 7.2 Maintaining WADA Approval

An APMU shall continue to function if the Laboratory's accreditation is suspended, provided that the APMU continues to meet other criteria for approval, and that any non-conformities related to the Suspension of the Laboratory's accreditation do not

have an impact on the APMU.<sup>7</sup> The APMU's approval shall be revoked if the *WADA* accreditation of the associated Laboratory is revoked.

#### 7.2.1 Minimum number of Passports and APMU Reports

In order to maintain proficiency, *WADA*-approved APMUs are required to review a minimum number of Passports and provide APMU Reports for Passports of *Code-compliant Passport Custodians* (as determined by *WADA*). *WADA* shall monitor the total number of Passports under the responsibility of the APMU and the number of APMU Reports issued by the APMU. If the number falls below 100 haematological Passports or 500 steroidal Passports per year, or the number of APMU Reports for haematological Passports or steroidal Passports falls below 200 or 500, respectively, *WADA* APMU approval may be suspended or revoked.

#### 7.2.2 Documenting compliance with the *WADA* APMU Code of Ethics

The APMU shall annually provide to *WADA* a letter of compliance with the provisions of the APMU Code of Ethics (Appendix B), signed by the APMU director. All APMU personnel shall sign the *WADA* APMU Code of Ethics on a yearly basis and the signed documents shall be kept as part of their personnel file. The APMU may be asked to provide documentation of compliance with the provisions of the APMU Code of Ethics.

#### 7.2.3 Documenting sharing of knowledge

The APMU shall proactively share knowledge with other *WADA*-approved APMUs. The APMU should participate at least once annually in a *WADA* working group or an anti-doping symposium or conference. The APMU shall supply an annual report on sharing of knowledge with *WADA*. A description of this sharing of knowledge is provided in the *WADA* APMU Code of Ethics (Appendix B).

#### 7.2.4 Maintaining professional liability insurance coverage

The APMU shall maintain an ongoing professional liability risk insurance coverage or equivalent which covers the APMU to an amount of no less than 2 million USD annually, and should ensure that the Expert panel has suitable professional liability risk insurance or equivalent coverage. Proof of the corresponding coverage shall be provided to *WADA* upon request.

#### 7.2.5 APMU compliance monitoring by *WADA*

*WADA* shall monitor the compliance of APMUs against the requirements listed in applicable *International Standards* and Technical Documents. In addition, *WADA* shall

---

<sup>7</sup> Suspension or revocation of APMU approval shall not be considered in decisions on Suspension or Revocation of Laboratory accreditation unless the APMU non-compliance has a clear impact on the function of the Laboratory.

also conduct at least an annual review of APMU compliance and any other relevant information received or collected by *WADA* to assess the overall performance of each APMU and to decide its approval status.

#### 7.2.6 APMU assessment by *WADA*

*WADA* reserves the right to conduct document-based audits as well as inspect and assess the APMU through on-site assessments at any time, at *WADA*'s expense. The notice of an on-site assessment will be made in writing to the APMU director. In exceptional circumstances, the on-site assessment may be unannounced.

#### 7.2.7 Suspension or revocation of approval

Suspension or revocation of APMU approval may occur whenever the APMU fails to comply with applicable *International Standards* and/or Technical Documents, or where such measure is otherwise required in order to protect the interests of the Anti-Doping Community.

Without limitation, the following non-conformities in the routine operations of an APMU may be considered in support of suspension:

- Failure to comply with any of the requirements listed in applicable *International Standards* and/or Technical Documents;
- Failure to cooperate with *WADA* or the relevant Testing Authority in providing documentation;
- Non-compliance(s) with the APMU Code of Ethics;
- Major changes in key staff without proper and timely notification to *WADA*;
- Failure to cooperate in any *WADA* inquiry in relation to the activities of the APMU;
- Non-compliance(s) identified from APMU on-site assessment(s); or
- Loss of resources jeopardizing the quality and/or viability of the APMU.

Non-compliance(s) in APMU performance will be assessed by *WADA* on a case-by-case basis considering the severity and consequences to the anti-doping system. Evidence of serious or multiple non-compliance(s) will be reported by *WADA* to an external assessment panel, who will make a recommendation to *WADA* regarding the approval status of the APMU and the required corrective actions and associated deadlines. *WADA* reserves the right to provisionally suspend an APMU's approval pending a full investigation. Such a decision may be taken by the Chair of *WADA*'s Executive Committee.

The period and terms of suspension shall be proportionate to the seriousness of the non-compliance(s) and the need to ensure reliable management of *Athlete Passports*. A period of suspension shall be of a duration to be decided by *WADA* and up to a

maximum of six (6) months, during which time any non-conformity(ies) must be corrected and such correction documented and reported to *WADA*. If the non-conformity(ies) is/are not corrected during the initial suspension period, the suspension shall either be further extended or the APMU approval revoked. The suspension period may be extended up to a maximum of an additional six (6) months, based on justifiable delays in implementing the satisfactory corrective actions. If the APMU has provided evidence determined to be satisfactory by *WADA* that the non-compliance(s) are corrected, the APMU's approval shall be re-instated. If the APMU has not provided evidence determined to be satisfactory by *WADA* at the end of the extended suspension period, not to exceed twelve (12) months, the APMU's approval shall be revoked.

During the period of suspension of the APMU, the management of all *Athlete Passports* shall be transferred by the Passport Custodian to another *WADA*-approved APMU.

The *WADA* Executive Committee shall revoke the approval of any APMU if it determines that revocation is necessary to ensure reliable management of *Athlete Passports*. Revocation may be based on, but not limited to, the following non-compliances in the routine operations of an APMU:

- Repeated suspensions of *WADA* APMU approval;
- Systematic failure to comply with applicable *International Standards* and/or Technical Documents;
- Failure to correct a lack of compliance with any of the requirements listed in applicable *International Standards* and/or Technical Documents during a suspension period;
- A serious or repeated violation of the APMU Code of Ethics;
- Repeated and/or continuous failure to cooperate in any *WADA* inquiry in relation to the activities of the APMU;
- Serious non-compliance(s) identified from APMU on-site assessment(s); or
- Loss of resources jeopardizing the quality and/or viability of the APMU.

#### 7.2.8 Appeals

*WADA's* decision to suspend or revoke an APMU's approval may be appealed in writing by the APMU before *CAS* within twenty-one (21) calendar days of the decision notification.

## 8.0 Passport Management and Administration

The APMU shall manage all Passports under the custody of the Passport Custodian.

## 8.1 Passport Review Process

The APMU shall carry out the Passport review process as described in Annex L of the ISTI.

### 8.1.1 When assessing a newly matched *Sample* in a Passport:

- The APMU shall assess the validity of individual *Samples* contained within the Passport in *ADAMS* and address any observed irregularities according to Article 8.2 by updating the APMU Report.
- The APMU shall review any new *Samples* within the updated Passport and provide *Target Testing*, *Sample* analysis or other recommendations via the APMU Report as required.<sup>8</sup>
- The APMU may request further information from the Passport Custodian including, but not limited to, circumstances and details of *Sample* collection, transport, and analysis, redacted *Athlete* competition schedule, travel history, *Athlete* performance, redacted *Athlete* medical information, information on an *Adverse Analytical Finding (AAF)* that is potentially relevant in the context of the Passport, or altitude/whereabouts information which may help them interpret the new *Sample*.
- If the APMU deems necessary, or upon *ADO* request after reviewing the updated Passport, such as if the APMU identifies suspicious features in the profile, the APMU shall send the Passport to an Expert for review.

### 8.1.2 When assessing a Passport that generated an *ATPF*:

- The APMU shall review any previous APMU Reports associated with the Passport.
- The APMU shall assess the validity of individual *Samples* contained within the Passport in *ADAMS*, address any irregularities according to Article 8.2 and update the APMU Report accordingly.
- The APMU shall evaluate the need for urgent *Target Testing* of the *Athlete* and communicate *Testing* recommendations to the *ADO* via the APMU Report as required.

---

<sup>8</sup> One of the benefits of the *ABP* is the ability to focus resources on atypical results requiring attention. As such, it is not mandatory for an APMU to review all newly matched *Samples* under their responsibility that do not generate a specific notification requiring mandatory follow-up. Nevertheless, at the discretion of the *ADO*, an APMU may be requested to review normal Passports.

- The APMU shall assess the need for additional analysis of existing *Samples* by specific methods (*e.g.*, Erythropoiesis-Simulating Agents [ESAs], Gas Chromatography – Combustion - Isotope Ratio Mass Spectrometry [GC/C/IRMS], etc.) and communicate these to the *ADO* via the APMU Report as required.
- If an Expert has previously recommended that follow-up *Testing* include a minimum number of *Samples* before further review of an *Athlete's Passport* data, the APMU may delay sending the Passport for review until the planned number of *Samples* have been analyzed.
- If, after managing the *Sample* validity, the Passport remains atypical, the APMU shall, without delay, send the Passport for review in *ADAMS* by an Expert according to Article L.2.2 of the ISTI. In the event of an Expert opinion of:
  - “Likely doping” - the APMU shall update the APMU Report indicating “likely doping”, specifying any detailed analysis or *Testing* recommendations from the Expert (if provided), and continue the Passport review process according to Article L.3 of the ISTI.
  - “Passport suspicious” - the APMU shall update the APMU Report indicating “Passport suspicious”, highlighting the main atypical features, and outline a *Target Testing* strategy (if necessary) based on the Expert recommendations, or recommend further analysis (*e.g.*, GC/C/IRMS).
  - “Normal” - the APMU shall update the APMU Report indicating “Normal”, summarizing the review by the Expert and outlining any *Testing* recommendations provided by the Expert.
  - “Likely medical condition” - the APMU shall update the APMU Report indicating “Likely medical condition” with submission to additional Experts if recommended in the Expert evaluation, and should inform the *Athlete* via the *ADO*.

8.1.3 When assessing a *Sample* that generated an *Atypical Passport Finding - Confirmation Procedure Request (ATPF-CPR)* or a *Suspicious Steroid Profile Confirmation Procedure Request (SSP-CPR)*:

- The APMU shall assess the validity of the *Sample* generating the Confirmation Procedure Request in *ADAMS*, address any irregularities according to Article 8.2 and update the APMU Report accordingly.
- Where the APMU finds that Confirmation Procedure(s) is/are not necessary according to the Technical Document for Endogenous Anabolic

---

Androgenic Steroids (TDEAAS), the APMU shall update the APMU Report accordingly and notify the Laboratory not to proceed with the Confirmation Procedure(s).

#### 8.1.4 Expert review of normal Passports

The APMU should provide the Experts from time to time with Passports for review, even when the values are within normal limits and presenting no suspicious elements, as this will ensure that Experts are provided a balanced perspective on the *Athletes' Passports*.

### 8.2 Management of *Sample* Validity

8.2.1 The APMU shall assess and manage the validity of urine and *ABP* blood *Samples* in *ADAMS* according to applicable *International Standards* and Technical Documents, including the International Standard for Laboratories (ISL), the *ISTI* and the *TDEAAS*.

8.2.2 Any changes in *Sample* validity made by the APMU shall be noted in applicable fields in *ADAMS* and in the APMU Report.

8.2.3 Where multiple *Samples* were provided by an *Athlete* during a single Sample Collection Session and are present in a Passport, the APMU shall invalidate all but one *Sample* based on assessment by the APMU.

8.2.4 Where multiple *Samples* were provided by an *Athlete* on the same day from different Sample Collection Sessions and are present in a Passport, the APMU may invalidate all but one *Sample* after assessment by the APMU in consultation with the concerned *ADO(s)*.

8.2.5 For urine *Samples* where a confounding factor is detected by the Laboratory (e.g., alcohol), the APMU may invalidate the *Sample* when it is considered to affect the sensitivity of the Adaptive Model to detect changes in future *Samples*.

8.2.6 For *ABP* blood *Samples* of suspicious profiles where the Blood Stability Score (BSS) could not be calculated, the APMU shall assess the collection-to-analysis time (CAT), any available temperature logger data, and the potential degradation of blood *Markers* in order to evaluate *Sample* validity, liaising with (an) Expert(s) as required.

### 8.3 The APMU Report

The APMU Report is a central element in the administrative sequence of the *ABP* that shall be entered and maintained by the APMU in *ADAMS*. The APMU Report provides an up-to-date overview of the current status of an *Athlete's Passport* together with recommendations, as appropriate, for efficient follow-up by the Passport Custodian.

The APMU Report serves to update the Passport Custodian, *WADA* and other *ADOs* with whom the Passport is shared. In addition, it provides a record of events associated with a Passport in *ADAMS*.

The APMU Report may include, without limitations:

- Assessments of *Sample* validity by the APMU and/or Experts;
- Recommendations for complementary Analytical Testing (*e.g.*, ESAs, HIF stabilizers, confirmation of steroid profile, GC/C/IRMS, long-term steroid *Metabolites*, IGF-I, etc.) on *Samples* collected;
- Recommendations for further Analytical Testing on *Samples* collected previously;
- Recommendations for storing of *Samples* for extended periods of time for Further Analysis;
- *Target Testing* recommendations based on available data and Experts' recommendations; and
- A summary of any recent Expert reviews.

8.3.1 APMU Reports shall be written in English and should use language which maintains the strict anonymity of the *Athlete*.

8.3.2 The APMU Report shall not contain any reference to an *AAF* that may be known to the APMU, with the exception of when the *AAF* is used by the APMU as a reason not to perform Confirmation Procedure(s) following an *ATPF-CPR* or *SSP-CPR* for the steroid profile (see *TDEAAS*). If the APMU assessment leads to an Expert review, the APMU may, however, separately inform the Expert(s) of the existence of the *AAF*. Depending on the result of the Expert review, the APMU shall further inform the Result Management Authority managing the *AAF* of the result of the Expert review, via the Passport Custodian, if that information is potentially relevant in the context of the result management based on the *AAF*.<sup>9</sup>

8.3.3 *Target Testing* recommendations shall be included in the APMU Report with a sufficient level of detail for the Passport Custodian to conduct effective, timely and appropriate *Testing*.

---

<sup>9</sup> While Passport sharing is strongly encouraged to enhance *ADO* efficiencies and program effectiveness through exchange of information and mutual recognition of program outcomes, this must be carried out within the framework of the *ISPPPI* and Article 14.1.4 of the *Code*. The information regarding an *AAF* shall therefore not be recorded in the APMU Report and shall not be disclosed unnecessarily. Only those individuals and/or organizations involved in the applicable results management process should be privy to this information.

## 8.4 Compiling the ABP Documentation Package

8.4.1 The APMU shall be responsible for compiling the ABP Documentation Package using the template provided by *WADA*. The Passport Custodian shall collect information and bear the cost of compiling ABP Documentation Packages unless it has established an agreement to share the costs with relevant Testing Authorities.

8.4.2 Upon request by the APMU, the *ADO* shall provide a detailed *Athlete* competition and altitude schedule, relevant information from *Doping Control* forms, temperature logger and Chain of Custody documentation to the APMU.

8.4.3 The APMU shall confer with the Expert panel to determine the scope of such compilation, including the recommended elements and the number of tests that need to be included. It is only mandatory to have a full Laboratory Documentation Package for those tests that are deemed essential by the Expert panel. Other relevant tests, for example those that confirm the baseline levels of a *Marker*, only require a Laboratory Certificate of Analysis. If the Passport Custodian is not the Testing Authority of the test requiring Laboratory documentation, the Passport Custodian shall coordinate with the Testing Authority to obtain such documentation.

8.4.4 The following key information shall be included for both Haematological and Steroidal Modules of the ABP Documentation Package:

- For the *Athlete*: age (excluding the date of birth), gender, and sport/discipline;
- For all tests: date and time of test, *ADAMS* ordinal number of the test in the Passport, *Sample* code number, and biological data and results obtained by the Adaptive Model;
- For tests selected by the APMU and Expert panel: internal Laboratory (or WADA-Approved Laboratory for the ABP) *Sample* number, *Competition* information, Chain of Custody documentation (including *Sample* collection date and time, and *Sample* analysis date and time), information from the *Doping Control* forms for each *Sample* collected during the period; and
- A compilation of the latest reviews from the Experts or the joint Expert opinion, as applicable.

For the Haematological Module, the following additional information shall be provided for the tests selected by the APMU and Expert panel:

- Temperature profile during the transportation of the blood *Sample* and, when available, the BSS;

- 
- Laboratory (or WADA-Approved Laboratory for the ABP) documentation, including blood results, scattergrams, and internal and external quality controls; and
  - Answers of the *Athlete* from the *ABP* Supplementary Report Form recorded as part of a Sample Collection Session.

For the Steroidal Module, the following additional information shall be provided for the tests selected by the APMU and Expert panel:

- pH of the urine *Sample*;
- Specific gravity (SG) of the urine *Sample*;
- Laboratory documentation, including screening and confirmed (when applicable) values of steroid concentrations and ratios;
- GC/C/IRMS results, when applicable;
- Indication of ethanol consumption: urinary concentrations of ethanol and/or ethanol *Metabolite(s)*;
- Indication of microbial growth, including at least 5 $\alpha$ -androstane/A and/or 5 $\beta$ -androstane/Etio ratio; and
- Information on the presence or absence of confounding factors that may influence the "steroid profile", such as human chorionic gonadotrophin (hCG), ketoconazole, and 5 $\alpha$ -reductase inhibitors.

## TD2019APMU Appendix A

### ABP Expert Code of Conduct Declaration

As an Expert engaged by **[name of the APMU]** to serve as a member of an *Athlete Biological Passport (ABP) Expert* panel, I, the undersigned, \_\_\_\_\_, affirm and acknowledge that, by signing this declaration, I am bound by the terms of such declaration.

#### **1.0 Passport Review**

I shall review all *ABP* cases in accordance with applicable *WADA* standards and established scientific knowledge and practices.

I understand that I shall not review Passports from individual *Athletes* on a private basis or from individuals or organizations acting on their behalf outside of standard anti-doping protocols under the World Anti-Doping Code.

#### **2.0 Confidentiality**

I understand that the nature of my participation as a member of the aforementioned panel is such that I shall come into contact with or be made aware of sensitive and Confidential Information.

The term "Confidential Information" means all nonpublic information shared throughout my mandate as an *ABP Expert*, information that is identified in writing as CONFIDENTIAL at the time of disclosure or the circumstances surrounding its disclosure, and information that reasonably should be considered as confidential. Confidential Information includes, without limitation (i) nonpublic information relating to technical or non-technical data, algorithms, formulas, patterns, compilations, programs, devices, methods, techniques, drawings, processes, products, services, or lists of actual or potential customers or suppliers which is not commonly known by or available to the public, technology, business plans and methods, promotional and marketing activities, finances and other business affairs, (ii) third-party information that the Disclosing Party is obligated to keep confidential, and (iii) the nature, context and existence of the relationship created by my nomination as an *ABP Expert*, discussion or negotiations between the people involved in this relation. The term "Confidential Information" also includes any modifications or derivatives that contain or are based upon such Confidential Information, including analysis, reports or summaries of that information.

I swear or solemnly state that, as a member of an *ABP Expert* panel of **[name of the organization]**, I shall respect all of the requirements relating to the confidentiality of the information that I receive or that is brought to my attention in any way whatsoever during the course of my duties and functions throughout and beyond the duration of my participation.

With the exception of legal obligations, authorisation by virtue of my office, the order of a court or law enforcement agency of competent jurisdiction, or the express authorisation of **[person in charge of the organization]**, I shall not reveal or hand over to anybody, particularly to representatives of the media, any confidential information or document that is brought to my attention or is in my possession, either directly or indirectly through my participation as a member of an *ABP Expert* panel of **[name of the organization]**, excluding information that has already been made public or is in my possession independently of **[name of the organization]**. I shall not use my title as member of an *ABP Expert* panel for any public declaration.

Furthermore, I understand that the violation of my confidentiality obligation as described herein may result in possible legal proceedings against me and the immediate termination of my participation as a member of an *ABP Expert* panel of **[name of the organization]**.

### **3.0 Conflicts of Interest**

In the event of any conflict of interest with a party to the evaluation for an *Athlete's Passport* that an *ABP Expert* panel of **[name of the organization]** may have to handle, I shall immediately inform **[person in charge of the organization]** and abstain from taking part in the decision procedure for the specific case in question.

### **4.0 Conduct Detrimental to the Anti-Doping Program**

I shall not engage in conduct or activities that undermine or are detrimental to the anti-doping programs of *WADA*, an International Federation, a *National Anti-Doping Organization*, a *National Olympic Committee*, a *Regional Anti-Doping Organization*, a *Major Event Organization*, or the International Olympic Committee or International Paralympic Committee. Such conduct could include, but is not limited to, conviction for fraud, embezzlement, perjury, etc., or knowledge of such, that would cast doubt on the integrity of the relevant anti-doping program(s).

I shall not provide counsel, advice or information to *Athletes* or other *Persons* regarding techniques or methods that may mask the detection of, alter the metabolism of, or suppress the excretion of a *Prohibited Substance* or *Marker(s)* of a *Prohibited Substance* or *Prohibited Method*.

Outside the context of an arbitration hearing, I shall not provide information to an *Athlete* or *Athlete Support Personnel* or any other *Person* about a *Testing* method that might assist the *Athlete* in avoiding detection of the *Use of a Prohibited Substance* or *Prohibited Method*. I shall not assist an *Athlete* in avoiding collection of a representative *Sample* (e.g., advice on masking or detection windows). This paragraph does not prohibit presentations to educate *Athletes*, students, or others concerning anti-doping programs.

If I am requested by any party or a tribunal or court of competent jurisdiction to appear as an expert witness, I understand that I am expected to provide an independent, scientifically valid expert testimony.

I shall not issue (publish) any public warning statements related to findings observed during Passport reviews. The responsibility for evaluation of these findings with further action and publication, if considered necessary, shall be left to the relevant *Anti-Doping Organization(s)*.

## 5.0 Declaration

By signing this declaration, I declare that I will abide by the Code of Conduct as described, and that my failure to abide by the Code of Conduct will result in the immediate termination of my participation as a member of an *ABP Expert* panel of **[name of the organization]**, in addition to any disciplinary sanctions that could be imposed against me by a disciplinary panel of competent jurisdiction.

DATED THE \_\_\_\_\_ DAY OF \_\_\_\_\_, 20\_\_\_\_\_

BY \_\_\_\_\_

(SIGNATURE)

## TD2019APMU Appendix B

### Athlete Passport Management Unit Code of Ethics

#### 1.0 Confidentiality

The nature of the responsibilities of the Athlete Passport Management Unit (APMU) is such that the APMU shall come into contact with or be made aware of sensitive and Confidential Information.

The term "Confidential Information" means all non-public information shared throughout the mandate of the APMU, information that is identified in writing as CONFIDENTIAL at the time of disclosure or the circumstances surrounding its disclosure, and information that reasonably should be considered as confidential. Confidential Information includes, without limitation (i) non-public information relating to technical or non-technical data, algorithms, formulas, patterns, compilations, programs, devices, methods, techniques, drawings, processes, products, services, or lists of actual or potential customers or suppliers which is not commonly known by or available to the public, technology, business plans and methods, promotional and marketing activities, finances and other business affairs, (ii) third-party information that the Disclosing Party is obligated to keep confidential, and (iii) discussion or negotiations between the relevant people involved. The term "Confidential Information" also includes any modifications or derivatives that contain or are based upon such Confidential Information, including analysis, reports or summaries of that information.

APMUs shall respect all of the requirements relating to the confidentiality of the information obtained in any way whatsoever during the course of their activities throughout and beyond the period of APMU approval by *WADA*.

With the exception of legal obligations, authorization by the Passport Custodian, or the order of a court or law enforcement agency of competent jurisdiction, an APMU shall not reveal or hand over to anybody, particularly to representatives of the media, any confidential information or document that is obtained, either directly or indirectly through its activities, excluding information that has already been made public or is its possession independently of the Passport Custodian. The director of the APMU, their delegates and APMU personnel shall not discuss or make any comment to the media on individual Passports or results without the express consent of the organization that is asserting the *Adverse Passport Finding (APF)* in adjudication (i.e., the Passport Custodian or *WADA*).

## 2.0 Passport Management

APMUs shall manage Passports in the *Anti-Doping Administration and Management System (ADAMS)* on behalf of the Passport Custodian in accordance with the requirements of the TDAPMU, Annex L of the International Standard for Testing and Investigations (ISTI), and other applicable *International Standards* and Technical Documents.

APMUs shall not manage or review Passports from individual *Athletes* on a private basis or from individuals or organizations acting on their behalf.

The APMU shall not provide services in a *Doping Control* adjudication, unless specifically requested by the responsible Passport Custodian, *WADA*, or a Hearing Body.

## 3.0 Sharing of Knowledge

When the APMU identifies a pattern in a Passport that may be attributed to the *Use* of a new form of *Prohibited Substance* or *Prohibited Method*, the APMU shall share such information with *WADA* within sixty (60) days.

Sharing of knowledge can occur by participation in scientific meetings, publication of results of research, or sharing of specific details of Passport management, such as *Target Testing* strategies, approaches to managing *Sample* validity, information regarding confounding factors, or special analyses necessary for detection. The APMU director and staff shall participate in developing standards for best practice and enhancing uniformity of Passport management in the *WADA* approved APMU system.

## 4.0 Conduct Detrimental to the Anti-Doping Program

The APMU personnel shall not engage in conduct or activities that undermine or are detrimental to the World Anti-doping Program<sup>1</sup>. Such conduct could include, but is not limited to, fraud, embezzlement, perjury, etc., or knowledge of such, that would cast doubt on the integrity of the anti-doping program.

No APMU personnel shall provide counsel, advice or information to *Athletes* or others regarding techniques or methods used to mask or avoid detection of, alter metabolism of, or suppress excretion of a *Prohibited Substance* or *Marker(s)* of the *Use* of a *Prohibited Substance* or *Prohibited Method*.

---

<sup>1</sup> The World Anti-doping Program comprises the anti-doping programs of *WADA* and all *Code Signatories*, including *International Federations*, *National Anti-Doping Organizations*, *Regional Anti-Doping Organizations*, *Major Event Organizations*, the *International Olympic Committee* or the *International Paralympic Committee*.

Outside of information provided in the context of anti-doping proceedings, no APMU personnel shall provide information about *Marker(s)* of the *ABP* which could be used to avoid the detection of doping, to an *Athlete* or *Athlete Support Personnel*. No APMU staff shall assist an *Athlete* in avoiding collection of a representative *Sample* (e.g., advice on masking strategies or detection windows). This paragraph does not prohibit general presentations to educate *Athletes*, students, or others concerning anti-doping programs and *Prohibited Substances* or *Prohibited Methods*. Such provisions shall remain valid for a minimum of five (5) years following termination of the contractual relationship of any employee to an APMU.

If an APMU staff is requested to provide evidence in anti-doping proceedings, they are expected to provide independent, scientifically-valid expert testimony.

The APMU shall not issue (publish) any public warning statements related to the Passport findings. The responsibility for publication of these findings, if considered necessary, shall be left to a political decision-making body (e.g., *Anti-Doping Organization*, International Federation or *WADA*).

## **5.0 Breach and Enforceability**

A failure to respect any of the provisions of this Code of Ethics may result in the APMU being subject to disciplinary proceedings instituted by *WADA* to either suspend or revoke its APMU approval in accordance with Article 0 of the TDAPMU. In addition, a failure to respect any of the provisions of this Code of Ethics may result in APMU staff being subject to disciplinary action by the APMU, resulting in consequences beyond those stipulated under the TDAPMU, including potential termination of employment or, where applicable, the imposition of criminal charges.

## Part Four: Collaboration Agreement Template

A non-mandatory collaboration agreement template is contained herein to facilitate the exchange of relevant information and mutual recognition of *ABP* program outcomes between *ADOs* that share *Testing* jurisdiction over a single *Athlete* (e.g., *National Anti-Doping Organization* and *International Federation*). *Anti-Doping Organizations* will need to review and modify this template as necessary to ensure it complies with applicable laws.

### Collaboration Agreement

Between

[•]

(hereinafter referred to as “[A]” or as a “Party”)

and

[•]

(hereinafter referred to as “[B]” or as a “Party”; and collectively with [A], the “Parties”)

**WHEREAS** the principle of the *ABP* is to have a single Passport for each *Athlete*, managed by a single *Anti-Doping Organization (ADO)* referred to as the Passport Custodian;

**WHEREAS** [A] is an [*ADO*] that has *Testing* jurisdiction over certain *Athletes* and wishes to perform Passport Testing in respect of such *Athletes*;

**WHEREAS** [B] is an [*ADO*] that also has *Testing* jurisdiction over those same *Athletes* and also wishes to perform Passport Testing in respect of such *Athletes*;

**WHEREAS** [A] and [B] wish to establish a framework to govern the exchange of *ABP-Related Information* (as defined below) and the mutual recognition of *Athlete Biological Passport (ABP)* program outcomes between [A] and [B] to enhance the efficiency and effectiveness of their respective *ABP* programs.

**THEREFORE**, it is agreed upon between the Parties:

#### Clause 1 - Definitions

Capitalized and italicized terms used in this Agreement shall have the meanings ascribed to them under the World Anti-Doping Code (“*Code*”) while capitalized and underlined terms shall have the meanings ascribed thereto in an *International Standard*, both as amended from time to time. [For ease of reference, relevant definitions have been reproduced in Schedule 1 attached hereto.]

Additional definitions created for the purposes of this Agreement shall be capitalized and have the following meanings:

- 1.1 “*ABP-Related Information*” means any information related to the administration and management of an *ABP* program, including longitudinal profiles of biological Markers; results of the Adaptive Model on Markers data and other information relevant to the evaluation of Markers; APMU and Expert reviews; and *Doping Control* and results management information related to a relevant Passport.
- 1.2 “*Agreement*” means this Collaboration Agreement, including its preamble.
- 1.3 “*ABP Operating Guidelines*” means the most recent version of the *ABP Operating Guidelines* adopted by *WADA* and available on *WADA*’s website ([www.wada-ama.org](http://www.wada-ama.org)).
- 1.4 “*Representative*” means an employee, officer, Third-Party Agent or other designated adviser or agent of a Party.

## **Clause 2 – Passport Testing and Information Sharing**

- 2.1 Where appropriate and necessary to ensure proper coordination and efficient allocation of Passport Testing activities and resources between the Parties, the Parties agree to provide each other with:
  - (a) a list of *Athletes* (over which [A] and [B] both have *Testing* jurisdiction) within their respective Registered Testing Pool (RTP) or other testing pool (TP) who will be subject to *ABP Testing* in accordance with their test distribution plans (TDP), and to discuss the composition of such TDP with the other Party in advance; and
  - (b) a list of *Events* where each Party intends to conduct pre-*Competition ABP testing*.
- 2.2 For the avoidance of doubt, nothing in this Clause 2 shall prevent [A] or [B] from *Testing* any *Athlete* within its *Testing* jurisdiction for the purposes of its *ABP* at any time, irrespective of the *Athlete*’s status on [A] or [B]’s TDP.
- 2.3 [A] shall conduct *Testing* of the *Athletes* in [A]’s TDP, and [B] shall conduct *Testing* of *Athletes* in [B]’s TDP, including by means of *Target Testing*. For such purposes:
  - (a) Each of [A] and [B] is responsible for ensuring that it has proper *Testing* jurisdiction with regard to any *Testing* activities;
  - (b) Each of [A] and [B] is responsible for ensuring that *Samples* are collected in compliance with the *Code*, the *International Standards*, and the *ABP Operating Guidelines*;
  - (c) Each of [A] and [B] shall each bear its own costs of *Testing* (including the costs of storage, transportation and analysis of *Samples*); and

- (d) The Parties, either directly or through their respective APMUs may share ABP-Related Information with each other as regards the *Target Testing of Athletes* in [A]'s TDP or [B]'s TDP, as the case may be.
- 2.4 Each Party agrees that it shall, at its own cost, exclusively use *ADAMS*, and require its respective APMU to use *ADAMS*, for recording doping control forms and other ABP-Related Information relating to any *Athlete* tested as part of a Party's ABP program.
- 2.5 Where an *Athlete* within a Party's testing pool has been tested as part of a Party's ABP program, the relevant Party shall upload and record all relevant ABP-Related Information on *ADAMS*, or ensure that it is being uploaded and recorded by its APMU, as soon as reasonably practical following the test.
- 2.6 The Party designated as the Passport Custodian, in accordance with clause 3.1 below, agrees that it shall provide the other Party with read-only access to relevant *Athlete Passports* in *ADAMS*. The Parties acknowledge that they may also set specific sharing rules within *ADAMS* to permit each of them automatic access to Passports of Athletes over whom they both have *Testing* jurisdiction.
- 2.7 The Parties acknowledge and agree that where a Party has granted access to a Passport to the other Party within *ADAMS*, such other Party may share ABP-Related Information with its duly authorized Representatives (including its APMU and members of its Expert Panel) strictly for the purposes of its ABP program.
- 2.8 If for whatever reason a Passport or other relevant ABP-Related Information cannot be readily accessed by a Party through *ADAMS*, the Passport Custodian shall provide the relevant Passport or other information to the other Party in such other secure manner as the other Party may reasonably request.

### **Clause 3 – Passport Results Management Process**

- 3.1 For each *Athlete* included in both [A] and [B]'s Registered Testing Pool or other relevant testing pool, the Parties shall agree which Party should act as Passport Custodian to maximise the effectiveness and efficiencies of each Party's respective ABP program, and to ensure the Passport Custodian is the Party that conducts more frequent *Testing* in respect of a given *Athlete*.
- 3.2 The Passport Custodian is responsible for results management in accordance with the then-current TD on Result Management Requirements for the ABP adopted by WADA. For *Athletes* included in both [A] and [B]'s TDP, Passports shall be reviewed after each test by the APMU of the Passport Custodian independently of whether [A] or [B] was the Testing Authority that conducted the last Passport test.
- 3.3 To the extent this information is not available to the other Party via *ADAMS*, The Parties shall immediately notify each other in writing of the referral of any *Athlete's Passport* for review by the other Party's ABP Expert panel in accordance with the ABP Operating Guidelines, as well as the outcome of such review. The Parties shall also notify each other upon request of an updated list of the members of their ABP Expert panel.

- 3.4 For the avoidance of doubt, relevant *ABP-Related Information* collected by [A] and [B] should, whenever possible, be consolidated for the purposes of pursuing a potential anti-doping rule violation (ADRV) or other results management procedure against an *Athlete* in accordance with the *Code* and *International Standards*.
- 3.5 Where the Passport Custodian decides not to proceed with an asserted ADRV in connection with a Passport, such decision will not affect the ability of the other Party or *WADA* to appeal such decision.

#### Clause 4 –Privacy and Security

- 4.1 The Parties acknowledge and agree that the sharing of *ABP-Related Information* (including Personal Information) under this Agreement is necessary to allow each Party to effectively and efficiently manage its *ABP* program and otherwise fulfill its obligations under the *Code* and the *International Standards*.
- 4.2 The Parties agree and acknowledge that each Party is responsible for complying with applicable data protection, privacy and data security laws as well as the *Code* and the *International Standards* with respect to any *ABP-Related Information* exchanged pursuant to this Agreement.
- 4.3 Without limiting the generality of the foregoing, each Party shall:
- (a) ensure that it has a valid legal authority or basis to share *ABP-Related Information* with, or receive such information from, the other Party in connection with this Agreement, as the case may be;
  - (b) treat any *ABP-Related Information* that it receives from the other Party as confidential information at all times and only Process such information for the anti-doping purposes set out in this Agreement and in accordance with the *International Standard* for the Protection of Privacy and Personal Information (ISPPPI);
  - (c) protect any *ABP-Related Information* that it receives from the other Party by applying all necessary and appropriate security safeguards, including physical, organizational, technical, environmental and other measures to prevent against a Security Breach;
  - (d) only grant access and access privileges to any *ABP-Related Information* that it receives from the other Party to its duly authorized Representatives (including its APMU and members of its Expert panel) on a need-to-know basis;
  - (e) subject to clause 4.3(d) above, not disclose any *ABP-Related Information* that it receives from the other Party to any other *Person* without the express prior written consent of the other Party, unless the disclosure is otherwise required by law;
  - (f) ensure any *Person* (including any duly authorized Representative) with access to *ABP-Related Information* is informed of the confidential nature of such information, of the limited purposes for which it can be used, and has entered into a written agreement to preserve such confidentiality; and

- (g) notify the other Party promptly of any Security Breach affecting any *ABP*-Related Information received under this Agreement and take immediate steps to rectify any such Security Breach.

#### **Clause 5 – Effective Date and Termination**

- 5.1 This Agreement shall become effective as of the date of the latest signature appearing on the signature page below and will remain in effect until terminated, except for clause 4 (Privacy and Security) and sub-clause 5.4 of this Agreement which shall survive termination.
- 5.2 Either Party may terminate this Agreement for any reason by providing thirty (30) days' written notice to the other Party.
- 5.3 Either Party may terminate this Agreement immediately if the other Party commits a material breach of any term of this Agreement and (if such breach is remediable) fails to remedy that breach within a period of thirty (30) days after being notified in writing of the breach.
- 5.4 The Parties agree that after the effective date of termination of this Agreement, and subject to applicable data protection and privacy laws, each Party may continue to use all information provided to it by the other Party pursuant to this Agreement, provided that such information is only used for anti-doping purposes in accordance with the *Code* and the *International Standards* and continues to be maintained in accordance with the privacy and security requirements set out in this Agreement, the ISPPPI and applicable laws.

#### **Clause 6 – Authority**

- 6.1 The Parties hereby represent that they have the full power and authority to enter into and perform this Agreement, and the Parties know of no agreement, promises, or undertakings that would prevent the full execution and performance of this Agreement.
- 6.2 Notwithstanding the above and for the avoidance of doubt, the Parties acknowledge and agree that nothing in this Agreement affects or modifies their respective rights and obligations, and those of other relevant third parties, under the "Agreement Governing the Use and Sharing of Information in *ADAMS*" that the Parties entered into with *WADA*.

#### **Clause 7 - Indemnity**

Each Party (the "Breaching Party") shall indemnify and hold harmless the other Party (the "Non-Breaching Party") against any and all costs, charges, damages, expenses and losses (including costs incurred in recovering same) that are incurred by the Non-Breaching Party as a result of any breach of this Agreement by the Breaching Party up to a maximum of [•].

**Clause 8 – Miscellaneous**

- 8.1 This Agreement is intended to be the sole and complete statement of obligation of the Parties as to the subject matter hereof, and supersedes all previous agreements, understandings, negotiations and proposals as to such subject matter.
- 8.2 The failure of either Party at any time to demand strict performance of the terms of the Agreement shall not be construed as a waiver of the right to demand or receive complete performance of all rights, promises and covenants in this Agreement.
- 8.3 This Agreement does not establish either Party to be the agent of the other Party or create a joint venture or similar relationship between the Parties and no Party shall have the power to obligate or bind the other Party in any manner whatsoever.
- 8.4 Neither Party may assign, directly or indirectly, by operation of law, change of control or otherwise, this Agreement or any of its rights and obligations hereunder, without the prior written consent of the other Party, which shall not be unreasonably withheld.
- 8.5 The Parties agree that any and all amendments to this Agreement must be made in writing and be signed by both Parties.
- 8.6 If any provision or provisions of this Agreement is be held to be invalid, illegal, or unenforceable, such provision shall be severed from this Agreement to the extent required and the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
- 8.7 A *Person* who is not a party to this Agreement shall not have any rights under or in connection with this Agreement. The rights of the Parties to terminate, rescind or agree any variation, waiver or settlement under this Agreement are not subject to the consent of any *Person* that is not a party to this Agreement.
- 8.8 Section and other headings in this Agreement are for convenience of reference only and shall not constitute a part of or otherwise affect the meaning or interpretation of this Agreement.

**Clause 9 - Notices**

- 9.1 Any notice required to be given under this Agreement shall be in writing and shall be delivered personally, sent by email, fax or sent by commercial courier, to the other Party required to receive the notice at the contact information set out below:
- (a) [A]:  
For the attention of: [•]  
Address: [•]  
Email: [•]  
Fax number: [•]
- (b) [B]:

For the attention of: [•]  
Address: [•]  
Email: [•]  
Fax number: [•]

or at such other address, email or fax as the relevant Party may specify by notice in writing to the other Party.

9.2 Any notice shall be deemed to have been duly given:

- (a) if delivered personally, at the time of delivery at the address referred to in Clause 11.1;
- (b) if delivered by commercial courier, at the time of signature of the courier's receipt;
- (c) if delivered by email, at the date and time indicated on such email; or
- (d) if sent by fax, at the time of transmission.

## **Clause 10 – Applicable Law and Jurisdiction**

10.1 This Agreement and any dispute or claim arising out of or in connection with it or its subject matter shall be governed by and construed in accordance with the law of [•].

10.2 The Parties agree that any dispute, arguments or claims arising with respect to or in connection with the execution of this Agreement (as well as any subsequent amendment hereof, including, for example, its structure, validity, effectiveness, interpretation, execution, infringement or termination, and also any non-contractual claim relating hereto) shall be the object of an amicable resolution. In the absence of amicable resolution, the dispute shall be submitted to the exclusive jurisdiction of the Court of Arbitration for Sport (CAS) in Lausanne, Switzerland, and settled definitively in accordance with the Code of Sports-related Arbitration. The panel will consist of one arbitrator. The language of the arbitration will be [•].

## **Clause 11 - Signatories**

The signatories to this Agreement hereby warrant that they have read and agree to the terms, conditions and provisions of this Agreement, including any Appendices, and have full power and authority to sign for and bind their respective organizations.

## **Clause 12 - Counterparts**

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument.

**In the name and on behalf of**  
**[A]**

.....[Name, Position]

Date: \_\_\_\_\_

**In the name and on behalf of  
[B]**

\_\_\_\_\_

.....[Name, Position]

Date: \_\_\_\_\_